INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27001, 29867, 'Tegaserod', 'Intestinal Obstruction', 'The use of tegaserod is contraindicated in patients with a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.  Stimulation of gastrointestinal motility might be harmful in these conditions.', '3', '"Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27002, 27986, 'Tegaserod', 'Liver Diseases', 'The use of tegaserod is contraindicated in patients with moderate or severe hepatic impairment, as it has not been adequately studied for treatment in this population.  In subjects with mild hepatic impairment, mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tegaserod were 16% and 31% higher, respectively, compared to subjects with normal hepatic function.  No dosage adjustment is required in patients with mild hepatic impairment; however, caution is advised when using tegaserod in such patients.', '3', '"Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27003, 29867, 'Tegaserod', 'Liver Diseases', 'The use of tegaserod is contraindicated in patients with moderate or severe hepatic impairment, as it has not been adequately studied for treatment in this population.  In subjects with mild hepatic impairment, mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tegaserod were 16% and 31% higher, respectively, compared to subjects with normal hepatic function.  No dosage adjustment is required in patients with mild hepatic impairment; however, caution is advised when using tegaserod in such patients.', '3', '"Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27004, 27986, 'Tegaserod', 'Kidney Diseases', 'The use of tegaserod is contraindicated in patients with severely impaired renal function.  According to the manufacturer, no change in the pharmacokinetics of tegaserod was observed in subjects with severe renal impairment requiring hemodialysis (CrCl < 15 mL/min/1.73 m2).  However, the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the main pharmacologically inactive metabolite of tegaserod increased 2- and 10-fold, respectively, compared to healthy controls.  The clinical significance of this observation is unknown.  No dosage adjustment is required in patients with mild to moderate renal impairment.', '3', '"Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27005, 29867, 'Tegaserod', 'Kidney Diseases', 'The use of tegaserod is contraindicated in patients with severely impaired renal function.  According to the manufacturer, no change in the pharmacokinetics of tegaserod was observed in subjects with severe renal impairment requiring hemodialysis (CrCl < 15 mL/min/1.73 m2).  However, the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the main pharmacologically inactive metabolite of tegaserod increased 2- and 10-fold, respectively, compared to healthy controls.  The clinical significance of this observation is unknown.  No dosage adjustment is required in patients with mild to moderate renal impairment.', '3', '"Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27006, 27986, 'Tegaserod', 'Diarrhea', 'Tegaserod should not be initiated in patients who are experiencing or frequently experience diarrhea.  Tegaserod stimulates gastrointestinal motility and may cause diarrhea, usually within the first week of treatment.  Patients should contact their physician if they experience severe diarrhea during therapy, or if the diarrhea is accompanied by severe cramping, abdominal pain, or dizziness.', '2', '"Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27007, 29867, 'Tegaserod', 'Diarrhea', 'Tegaserod should not be initiated in patients who are experiencing or frequently experience diarrhea.  Tegaserod stimulates gastrointestinal motility and may cause diarrhea, usually within the first week of treatment.  Patients should contact their physician if they experience severe diarrhea during therapy, or if the diarrhea is accompanied by severe cramping, abdominal pain, or dizziness.', '2', '"Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27008, 25651, 'Telbivudine', 'Muscular Diseases', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine and telbivudine may commonly cause myopathy, including rare cases of rhabdomyolysis.  The myopathy may be dose-related and is characterized by persistent, unexplained muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values.  Therapy with these NRTIs should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  NRTI therapy should be interrupted if drug-related myopathy is suspected, and discontinued if myopathy is diagnosed.', '3', '"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Tyzeka (telbivudine)." IDEC Pharmaceuticals Corporation  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27009, 25651, 'Telbivudine', 'Diseases requiring hemodialysis', 'Telbivudine is removed by hemodialysis.  Up to four hours of hemodialysis can reduce systemic telbivudine exposure by approximately 23%.  Telbivudine should be administered after hemodialysis.  Following dose interval adjustment for creatinine clearance, no additional dose modification is necessary during routine hemodialysis.', '2', '"Product Information. Tyzeka (telbivudine)." IDEC Pharmaceuticals Corporation  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27010, 25651, 'Telbivudine', 'Kidney Diseases', 'Telbivudine is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), systemic exposure (AUC) of single-dose telbivudine increased by 26% in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min) and 136% in patients with end-stage renal disease managed on hemodialysis.  Renal clearance decreased by 66% and 91%, respectively, in patients with moderate and severe renal dysfunction (CrCl below 30 mL/min).  Adjustment of the dosing interval is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Tyzeka (telbivudine)." IDEC Pharmaceuticals Corporation  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27011, 6186, 'Bempedoic acid', 'Hepatic Insufficiency', 'Bempedoic acid has not been studied in patients with severe hepatic impairment (Child-Pugh C), therefore, caution is advised if used in these patients.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment (Child-Pugh A or B).', '2', '"Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27012, 7496, 'Bempedoic acid', 'Hepatic Insufficiency', 'Bempedoic acid has not been studied in patients with severe hepatic impairment (Child-Pugh C), therefore, caution is advised if used in these patients.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment (Child-Pugh A or B).', '2', '"Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27013, 6186, 'Bempedoic acid', 'Hyperuricemia', 'Bempedoic acid can elevate serum uric acid.  Caution is advised in patients with a history of gout.  Assess uric acid levels periodically and monitor any signs or symptoms of hyperuricemia.', '2', '"Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27014, 7496, 'Bempedoic acid', 'Hyperuricemia', 'Bempedoic acid can elevate serum uric acid.  Caution is advised in patients with a history of gout.  Assess uric acid levels periodically and monitor any signs or symptoms of hyperuricemia.', '2', '"Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27015, 6186, 'Bempedoic acid', 'Kidney Diseases', 'There is limited experience with the use of bempedoic acid in patients with severe renal impairment, and the drug has not been studied in patients with end-stage renal disease (ESRD) receiving dialysis.  Caution is advised if used in these patients.', '2', '"Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27016, 7496, 'Bempedoic acid', 'Kidney Diseases', 'There is limited experience with the use of bempedoic acid in patients with severe renal impairment, and the drug has not been studied in patients with end-stage renal disease (ESRD) receiving dialysis.  Caution is advised if used in these patients.', '2', '"Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27017, 6186, 'Bempedoic acid', 'Tendon Injuries', 'Bempedoic acid has been associated with an increased risk of tendon rupture or injury.  Ruptures involving the rotator cuff, biceps, or Achilles tendon have been reported.  Risk increases in patients over 60, those on corticosteroid or fluoroquinolone treatment, patients with renal failure, and patients with previous tendon disorders.  Consider an alternative therapy in patients with a history of tendon disorders or rupture.  Discontinue treatment if rupture of a tendon occurs or consider discontinuation if the patient experiences joint pain, swelling, or inflammation.', '2', '"Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27018, 7496, 'Bempedoic acid', 'Tendon Injuries', 'Bempedoic acid has been associated with an increased risk of tendon rupture or injury.  Ruptures involving the rotator cuff, biceps, or Achilles tendon have been reported.  Risk increases in patients over 60, those on corticosteroid or fluoroquinolone treatment, patients with renal failure, and patients with previous tendon disorders.  Consider an alternative therapy in patients with a history of tendon disorders or rupture.  Discontinue treatment if rupture of a tendon occurs or consider discontinuation if the patient experiences joint pain, swelling, or inflammation.', '2', '"Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27019, 2472, 'Telmisartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27020, 15252, 'Telmisartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27021, 16225, 'Telmisartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27022, 21692, 'Telmisartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27023, 21693, 'Telmisartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27024, 22693, 'Telmisartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27025, 22694, 'Telmisartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27026, 29869, 'Telmisartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27027, 2472, 'Telmisartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27028, 15252, 'Telmisartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27029, 16225, 'Telmisartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27030, 21692, 'Telmisartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27031, 21693, 'Telmisartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27032, 22693, 'Telmisartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27033, 22694, 'Telmisartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27034, 29869, 'Telmisartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27035, 2472, 'Telmisartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension." Am J Cardiol 75 (1995):  793-5|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Weber MA, Bryyny RL, Pratt JH, et al. "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Mcintyre M, Macfadyen RJ, Meredith PA, Menard J, Brunner HR, Insuasty J, Reid JL "Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man." J Cardiovasc Pharmacol 25 (1995):  994-1000|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors." J Hypertens 13 Suppl (1995):  s77-80|Tikkanen I, Omvik P, Jensen HA "Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension." J Hypertens 13 (1995):  1343-51|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM "Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension." Clin Ther 18 (1996):  411-28|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." Clin Ther 18 (1996):  608-25|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|Karlberg BE, Lins LE, Hermansson K "Efficacy and safety of telmisartan, a selective AT(1) receptor antagonist, compared with enalapril in elderly patients with primary hypertension." J Hypertens 17 (1999):  293-302|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27036, 15252, 'Telmisartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension." Am J Cardiol 75 (1995):  793-5|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Weber MA, Bryyny RL, Pratt JH, et al. "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Mcintyre M, Macfadyen RJ, Meredith PA, Menard J, Brunner HR, Insuasty J, Reid JL "Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man." J Cardiovasc Pharmacol 25 (1995):  994-1000|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors." J Hypertens 13 Suppl (1995):  s77-80|Tikkanen I, Omvik P, Jensen HA "Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension." J Hypertens 13 (1995):  1343-51|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM "Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension." Clin Ther 18 (1996):  411-28|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." Clin Ther 18 (1996):  608-25|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|Karlberg BE, Lins LE, Hermansson K "Efficacy and safety of telmisartan, a selective AT(1) receptor antagonist, compared with enalapril in elderly patients with primary hypertension." J Hypertens 17 (1999):  293-302|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27037, 16225, 'Telmisartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension." Am J Cardiol 75 (1995):  793-5|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Weber MA, Bryyny RL, Pratt JH, et al. "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Mcintyre M, Macfadyen RJ, Meredith PA, Menard J, Brunner HR, Insuasty J, Reid JL "Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man." J Cardiovasc Pharmacol 25 (1995):  994-1000|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors." J Hypertens 13 Suppl (1995):  s77-80|Tikkanen I, Omvik P, Jensen HA "Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension." J Hypertens 13 (1995):  1343-51|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM "Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension." Clin Ther 18 (1996):  411-28|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." Clin Ther 18 (1996):  608-25|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|Karlberg BE, Lins LE, Hermansson K "Efficacy and safety of telmisartan, a selective AT(1) receptor antagonist, compared with enalapril in elderly patients with primary hypertension." J Hypertens 17 (1999):  293-302|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27038, 21692, 'Telmisartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension." Am J Cardiol 75 (1995):  793-5|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Weber MA, Bryyny RL, Pratt JH, et al. "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Mcintyre M, Macfadyen RJ, Meredith PA, Menard J, Brunner HR, Insuasty J, Reid JL "Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man." J Cardiovasc Pharmacol 25 (1995):  994-1000|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors." J Hypertens 13 Suppl (1995):  s77-80|Tikkanen I, Omvik P, Jensen HA "Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension." J Hypertens 13 (1995):  1343-51|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM "Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension." Clin Ther 18 (1996):  411-28|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." Clin Ther 18 (1996):  608-25|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|Karlberg BE, Lins LE, Hermansson K "Efficacy and safety of telmisartan, a selective AT(1) receptor antagonist, compared with enalapril in elderly patients with primary hypertension." J Hypertens 17 (1999):  293-302|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27039, 21693, 'Telmisartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension." Am J Cardiol 75 (1995):  793-5|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Weber MA, Bryyny RL, Pratt JH, et al. "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Mcintyre M, Macfadyen RJ, Meredith PA, Menard J, Brunner HR, Insuasty J, Reid JL "Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man." J Cardiovasc Pharmacol 25 (1995):  994-1000|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors." J Hypertens 13 Suppl (1995):  s77-80|Tikkanen I, Omvik P, Jensen HA "Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension." J Hypertens 13 (1995):  1343-51|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM "Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension." Clin Ther 18 (1996):  411-28|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." Clin Ther 18 (1996):  608-25|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|Karlberg BE, Lins LE, Hermansson K "Efficacy and safety of telmisartan, a selective AT(1) receptor antagonist, compared with enalapril in elderly patients with primary hypertension." J Hypertens 17 (1999):  293-302|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27040, 22693, 'Telmisartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension." Am J Cardiol 75 (1995):  793-5|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Weber MA, Bryyny RL, Pratt JH, et al. "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Mcintyre M, Macfadyen RJ, Meredith PA, Menard J, Brunner HR, Insuasty J, Reid JL "Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man." J Cardiovasc Pharmacol 25 (1995):  994-1000|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors." J Hypertens 13 Suppl (1995):  s77-80|Tikkanen I, Omvik P, Jensen HA "Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension." J Hypertens 13 (1995):  1343-51|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM "Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension." Clin Ther 18 (1996):  411-28|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." Clin Ther 18 (1996):  608-25|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|Karlberg BE, Lins LE, Hermansson K "Efficacy and safety of telmisartan, a selective AT(1) receptor antagonist, compared with enalapril in elderly patients with primary hypertension." J Hypertens 17 (1999):  293-302|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27041, 22694, 'Telmisartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension." Am J Cardiol 75 (1995):  793-5|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Weber MA, Bryyny RL, Pratt JH, et al. "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Mcintyre M, Macfadyen RJ, Meredith PA, Menard J, Brunner HR, Insuasty J, Reid JL "Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man." J Cardiovasc Pharmacol 25 (1995):  994-1000|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors." J Hypertens 13 Suppl (1995):  s77-80|Tikkanen I, Omvik P, Jensen HA "Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension." J Hypertens 13 (1995):  1343-51|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM "Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension." Clin Ther 18 (1996):  411-28|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." Clin Ther 18 (1996):  608-25|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|Karlberg BE, Lins LE, Hermansson K "Efficacy and safety of telmisartan, a selective AT(1) receptor antagonist, compared with enalapril in elderly patients with primary hypertension." J Hypertens 17 (1999):  293-302|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27042, 29869, 'Telmisartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension." Am J Cardiol 75 (1995):  793-5|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Weber MA, Bryyny RL, Pratt JH, et al. "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Mcintyre M, Macfadyen RJ, Meredith PA, Menard J, Brunner HR, Insuasty J, Reid JL "Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man." J Cardiovasc Pharmacol 25 (1995):  994-1000|Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors." J Hypertens 13 Suppl (1995):  s77-80|Tikkanen I, Omvik P, Jensen HA "Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension." J Hypertens 13 (1995):  1343-51|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM "Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension." Clin Ther 18 (1996):  411-28|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." Clin Ther 18 (1996):  608-25|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|Karlberg BE, Lins LE, Hermansson K "Efficacy and safety of telmisartan, a selective AT(1) receptor antagonist, compared with enalapril in elderly patients with primary hypertension." J Hypertens 17 (1999):  293-302|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27043, 2472, 'Telmisartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group." Circulation 91 (1995):  691-7|Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M "Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure." Circulation 88 (1993):  1602-9|Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD "Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers." Hypertension 21 (1993):  704-13|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure." J Hypertens Suppl 12 (1994):  s31-5|Abdelrahman AM, Burrell LM, Johnston CI "Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone." J Hypertens 11 Suppl 3 (1993):  s23-6|Rush JE, Rajfer SI "Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure." J Hypertens 11 Suppl 3 (1993):  s69-71|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Crozier I, Ikram H "The acute and chronic effects of losartan in heart failure." J Hypertens 13 Suppl (1995):  s59-61|Saine DR, Ahrens ER "Renal impairment associated with losartan." Ann Intern Med 124 (1996):  775|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|Pitt B, Segal R, Martinez FA, et al. "Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)." Lancet 349 (1997):  747-52|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27044, 15252, 'Telmisartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group." Circulation 91 (1995):  691-7|Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M "Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure." Circulation 88 (1993):  1602-9|Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD "Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers." Hypertension 21 (1993):  704-13|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure." J Hypertens Suppl 12 (1994):  s31-5|Abdelrahman AM, Burrell LM, Johnston CI "Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone." J Hypertens 11 Suppl 3 (1993):  s23-6|Rush JE, Rajfer SI "Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure." J Hypertens 11 Suppl 3 (1993):  s69-71|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Crozier I, Ikram H "The acute and chronic effects of losartan in heart failure." J Hypertens 13 Suppl (1995):  s59-61|Saine DR, Ahrens ER "Renal impairment associated with losartan." Ann Intern Med 124 (1996):  775|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|Pitt B, Segal R, Martinez FA, et al. "Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)." Lancet 349 (1997):  747-52|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27045, 16225, 'Telmisartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group." Circulation 91 (1995):  691-7|Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M "Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure." Circulation 88 (1993):  1602-9|Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD "Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers." Hypertension 21 (1993):  704-13|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure." J Hypertens Suppl 12 (1994):  s31-5|Abdelrahman AM, Burrell LM, Johnston CI "Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone." J Hypertens 11 Suppl 3 (1993):  s23-6|Rush JE, Rajfer SI "Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure." J Hypertens 11 Suppl 3 (1993):  s69-71|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Crozier I, Ikram H "The acute and chronic effects of losartan in heart failure." J Hypertens 13 Suppl (1995):  s59-61|Saine DR, Ahrens ER "Renal impairment associated with losartan." Ann Intern Med 124 (1996):  775|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|Pitt B, Segal R, Martinez FA, et al. "Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)." Lancet 349 (1997):  747-52|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27046, 21692, 'Telmisartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group." Circulation 91 (1995):  691-7|Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M "Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure." Circulation 88 (1993):  1602-9|Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD "Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers." Hypertension 21 (1993):  704-13|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure." J Hypertens Suppl 12 (1994):  s31-5|Abdelrahman AM, Burrell LM, Johnston CI "Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone." J Hypertens 11 Suppl 3 (1993):  s23-6|Rush JE, Rajfer SI "Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure." J Hypertens 11 Suppl 3 (1993):  s69-71|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Crozier I, Ikram H "The acute and chronic effects of losartan in heart failure." J Hypertens 13 Suppl (1995):  s59-61|Saine DR, Ahrens ER "Renal impairment associated with losartan." Ann Intern Med 124 (1996):  775|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|Pitt B, Segal R, Martinez FA, et al. "Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)." Lancet 349 (1997):  747-52|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27047, 21693, 'Telmisartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group." Circulation 91 (1995):  691-7|Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M "Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure." Circulation 88 (1993):  1602-9|Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD "Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers." Hypertension 21 (1993):  704-13|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure." J Hypertens Suppl 12 (1994):  s31-5|Abdelrahman AM, Burrell LM, Johnston CI "Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone." J Hypertens 11 Suppl 3 (1993):  s23-6|Rush JE, Rajfer SI "Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure." J Hypertens 11 Suppl 3 (1993):  s69-71|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Crozier I, Ikram H "The acute and chronic effects of losartan in heart failure." J Hypertens 13 Suppl (1995):  s59-61|Saine DR, Ahrens ER "Renal impairment associated with losartan." Ann Intern Med 124 (1996):  775|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|Pitt B, Segal R, Martinez FA, et al. "Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)." Lancet 349 (1997):  747-52|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27048, 22693, 'Telmisartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group." Circulation 91 (1995):  691-7|Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M "Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure." Circulation 88 (1993):  1602-9|Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD "Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers." Hypertension 21 (1993):  704-13|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure." J Hypertens Suppl 12 (1994):  s31-5|Abdelrahman AM, Burrell LM, Johnston CI "Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone." J Hypertens 11 Suppl 3 (1993):  s23-6|Rush JE, Rajfer SI "Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure." J Hypertens 11 Suppl 3 (1993):  s69-71|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Crozier I, Ikram H "The acute and chronic effects of losartan in heart failure." J Hypertens 13 Suppl (1995):  s59-61|Saine DR, Ahrens ER "Renal impairment associated with losartan." Ann Intern Med 124 (1996):  775|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|Pitt B, Segal R, Martinez FA, et al. "Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)." Lancet 349 (1997):  747-52|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27049, 22694, 'Telmisartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group." Circulation 91 (1995):  691-7|Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M "Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure." Circulation 88 (1993):  1602-9|Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD "Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers." Hypertension 21 (1993):  704-13|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure." J Hypertens Suppl 12 (1994):  s31-5|Abdelrahman AM, Burrell LM, Johnston CI "Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone." J Hypertens 11 Suppl 3 (1993):  s23-6|Rush JE, Rajfer SI "Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure." J Hypertens 11 Suppl 3 (1993):  s69-71|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Crozier I, Ikram H "The acute and chronic effects of losartan in heart failure." J Hypertens 13 Suppl (1995):  s59-61|Saine DR, Ahrens ER "Renal impairment associated with losartan." Ann Intern Med 124 (1996):  775|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|Pitt B, Segal R, Martinez FA, et al. "Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)." Lancet 349 (1997):  747-52|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27050, 29869, 'Telmisartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995):  405-11|Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group." Circulation 91 (1995):  691-7|Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M "Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure." Circulation 88 (1993):  1602-9|Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al. "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995):  37-46|Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD "Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers." Hypertension 21 (1993):  704-13|Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993):  732-8|Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure." J Hypertens Suppl 12 (1994):  s31-5|Abdelrahman AM, Burrell LM, Johnston CI "Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone." J Hypertens 11 Suppl 3 (1993):  s23-6|Rush JE, Rajfer SI "Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure." J Hypertens 11 Suppl 3 (1993):  s69-71|"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|Crozier I, Ikram H "The acute and chronic effects of losartan in heart failure." J Hypertens 13 Suppl (1995):  s59-61|Saine DR, Ahrens ER "Renal impairment associated with losartan." Ann Intern Med 124 (1996):  775|Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996):  625-36|Waeber B, Brunner HR "Angiotensin II antagonists: a new class of antihypertensive agent." Br J Clin Pract 50 (1996):  265-8|Gibbs CR, Ferner RE, Beevers DG "Angiotensin receptor antagonists - a new class of antihypertensive drug." J Clin Pharm Ther 21 (1996):  127-30|Ellis ML, Patterson H "A new class of antihypertensive therapy: angiotensin II receptor antagonists." Pharmacotherapy 16 (1996):  849-60|Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996):  1147-115|Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996):  s142-6|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|Pitt B, Segal R, Martinez FA, et al. "Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)." Lancet 349 (1997):  747-52|van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In ''t Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995):  22-9|McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL "Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormona effects in salt-deplete men." J Cardiovasc Pharmacol 28 (1996):  101-6|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27051, 2472, 'Telmisartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27052, 15252, 'Telmisartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27053, 16225, 'Telmisartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27054, 21692, 'Telmisartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27055, 21693, 'Telmisartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27056, 22693, 'Telmisartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27057, 22694, 'Telmisartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27058, 29869, 'Telmisartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27059, 2472, 'Telmisartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27060, 15252, 'Telmisartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27061, 16225, 'Telmisartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27062, 21692, 'Telmisartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27063, 21693, 'Telmisartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27064, 22693, 'Telmisartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27065, 22694, 'Telmisartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27066, 29869, 'Telmisartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27067, 2472, 'Telmisartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27068, 15252, 'Telmisartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27069, 16225, 'Telmisartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27070, 21692, 'Telmisartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27071, 21693, 'Telmisartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27072, 22693, 'Telmisartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27073, 22694, 'Telmisartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27074, 29869, 'Telmisartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '"Product Information. Cozaar (losartan)." Merck & Co., Inc  (2001):|"Product Information. Diovan (valsartan)." Novartis Pharmaceuticals  (2001):|"Product Information. Avapro (irbesartan)." Bristol-Myers Squibb  (2001):|"Product Information. Teveten (eprosartan)." SmithKline Beecham  (2001):|"Product Information. Atacand (candesartan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|"Product Information. Benicar (olmesartan)." Sankyo Pharma  (2002):|"Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27075, 2472, 'Telmisartan', 'Liver Diseases', 'Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine.  Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Patients with hepatic impairment or biliary obstruction may require a dosage adjustment.  The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.', '2', '"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27076, 15252, 'Telmisartan', 'Liver Diseases', 'Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine.  Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Patients with hepatic impairment or biliary obstruction may require a dosage adjustment.  The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.', '2', '"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27077, 16225, 'Telmisartan', 'Liver Diseases', 'Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine.  Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Patients with hepatic impairment or biliary obstruction may require a dosage adjustment.  The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.', '2', '"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27078, 21692, 'Telmisartan', 'Liver Diseases', 'Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine.  Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Patients with hepatic impairment or biliary obstruction may require a dosage adjustment.  The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.', '2', '"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27079, 21693, 'Telmisartan', 'Liver Diseases', 'Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine.  Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Patients with hepatic impairment or biliary obstruction may require a dosage adjustment.  The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.', '2', '"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27080, 22693, 'Telmisartan', 'Liver Diseases', 'Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine.  Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Patients with hepatic impairment or biliary obstruction may require a dosage adjustment.  The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.', '2', '"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27081, 22694, 'Telmisartan', 'Liver Diseases', 'Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine.  Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Patients with hepatic impairment or biliary obstruction may require a dosage adjustment.  The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.', '2', '"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27082, 29869, 'Telmisartan', 'Liver Diseases', 'Telmisartan is primarily eliminated by biliary excretion, and only a minute amount is excreted in the urine.  Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Patients with hepatic impairment or biliary obstruction may require a dosage adjustment.  The manufacturer recommends administering telmisartan therapy with caution in patients with liver disease or biliary obstruction.', '2', '"Product Information. Micardis (telmisartan)." Boehringer-Ingelheim  (2001):|McClellan KJ, Markham A "Telmisartan." Drugs 56 (1998):  1039-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27083, 0, 'Telithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27084, 0, 'Telithromycin', 'Hepatitis', 'The use of telithromycin is contraindicated in patients with previous history of hepatitis and/or jaundice associated with the use of any macrolide antibacterial agent.', '3', '"Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27085, 0, 'Telithromycin', 'Liver Diseases', 'Hepatic dysfunction, including elevated liver enzymes and hepatitis, with or without jaundice, has been reported with the use of telithromycin.  Although these events are generally reversible, liver failure resulting in transplantation or death has been reported rarely during postmarketing use.  Alcohol use may have been a contributing factor in some of the severe cases.  Therapy with telithromycin should preferably be avoided in patients with alcoholism, liver disease, or a prior history of hepatitis/jaundice associated with use of the drug.  Patients treated with telithromycin should be instructed to discontinue the drug and seek medical attention promptly if signs and symptoms of hepatic injury develop such as fever, pruritus, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.
The pharmacokinetics of telithromycin is not significantly altered in the presence of hepatic impairment due to a compensatory increase in renal elimination.  No dosage adjustment is necessary unless renal function is also severely impaired (CrCl < 30 mL/min).', '3', '"Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals  (2004):|Cantalloube C, Bhargava V, Sultan E, Vacheron F, Batista I, Montay G "Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment." Int J Antimicrob Agents 22 (2003):  112-21|Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP 3rd, Banks PM "Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review." Ann Intern Med 144 (2006):  E1-E6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27086, 0, 'Telithromycin', 'Myasthenia Gravis', 'Telithromycin is contraindicated in patients with myasthenia gravis.  There have been reports of fatal and life-threatening respiratory failure in patients with myasthenia gravis associated with the use of this drug.', '3', '"Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals  (2004):|Nieman RB, Sharma K, Edelberg H, Caffe SE "Telithromycin and myasthenia gravis." Clin Infect Dis 37 (2003):  1579', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27087, 0, 'Telithromycin', 'Long QT Syndrome', 'Telithromycin may prolong the QTc interval of the electrocardiogram in some patients.  QTC prolongation has been associated with an increased risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  No cardiovascular morbidity or mortality attributable to QTc prolongation occurred with telithromycin treatment in nearly 5000 patients in clinical efficacy trials, including 204 patients who had a prolonged QTc interval at baseline.  In addition, a pharmacokinetic study found no significant QT prolongation in 34 healthy volunteers at all heart rates tested following telithromycin administered as repeated doses of 800 mg or as single doses of up to 2400 mg.  Nevertheless, therapy with telithromycin should be avoided in patients with preexisting arrhythmia or congenital prolongation of the QTc interval.  It should also be avoided in the presence of proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia; clinically significant bradycardia; or concomitant use of class IA or III antiarrhythmic drugs or other medications that are known to produce an increase in the QTc interval.', '3', 'Demolis JL, Vacheron F, Cardus S, Funck-Brentano C "Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects." Clin Pharmacol Ther 73 (2003):  242-52|"Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals  (2004):|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27088, 0, 'Telithromycin', 'Diseases requiring hemodialysis', 'The effect of hemodialysis on removing telithromycin from the body has not been studied.  Doses should be given after the dialysis session on dialysis days.', '2', '"Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27089, 0, 'Telithromycin', 'Kidney Diseases', 'Telithromycin is eliminated by both renal and hepatic routes.  In a multiple-dose study of subjects with varying degrees of renal impairment, patients classified as having severely impaired renal function (CrCl < 30 mL/min) had a 1.4-fold increase in steady-state peak plasma concentration (Cmax) and a 1.9-fold increase in systemic exposure (AUC) of telithromycin compared to healthy volunteers following administration of 800 mg once daily for 5 days.  Renal excretion may serve as a compensatory elimination pathway for telithromycin in situations where metabolic clearance is impaired.  In one study, coadministration of ketoconazole (which inhibits metabolism of telithromycin via CYP450 3A4) in 2 patients with severe renal impairment resulted in a 4- to 5-fold increase in telithromycin AUC compared to that in healthy subjects with normal renal function receiving telithromycin alone.  Since patients with severe renal impairment are prone to conditions that may impair their metabolic clearance, telithromycin dosage should be reduced to 600 mg once daily in patients with severe renal impairment (CrCl < 30 mL/min), including those undergoing dialysis.  The dosage should be further reduced to 400 mg once daily if there is coexisting hepatic impairment.', '2', '"Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals  (2004):|Shi J, Montay G, Chapel S, et al. "Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment." J Clin Pharmacol 44 (2004):  234-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27090, 0, 'Tapentadol', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27091, 0, 'Tapentadol', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27092, 0, 'Tapentadol', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27093, 0, 'Tapentadol', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27094, 0, 'Tapentadol', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27095, 0, 'Tapentadol', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H "Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification ." J Clin Psychopharmacol 8 (1988):  441-2|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Morrison AB "Toxicity and abuse of hydrocodone bitartrate." Can Med Assoc J 120 (1979):  1338|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Azorlosa JL, Stitzer ML, Greenwald MK "Opioid physical dependence development - effects of single versus repeated morphine pretreatments and of subjects opioid exposure history." Psychopharmacology (Berl) 114 (1994):  71-80|Strode SW "Propoxyphene dependence and withdrawal." Am Fam Physician 32 (1985):  105-8|Wall R, Linford SM, Akhter MI "Addiction to Distalgesic (dextropropoxyphene)." Br Med J 280 (1980):  1213-4|Salguero CH, Villarreal JE, Hug CC Jr, Domino EF "Propoxyphene dependence." JAMA 210 (1969):  135-6|Claghorn JL, Schoolar JC "Propoxyphene hydrochloride, a drug of abuse." JAMA 196 (1966):  1089-91|Whittington RM "Dextropropoxyphene addiction." Lancet 2 (1979):  743-4|Collins GB, Kiefer KS "Propoxyphene dependence: an update." Postgrad Med 70 (1981):  57-61|Ng B, Alvear M "Dextropropoxyphene addiction--a drug of primary abuse." Am J Drug Alcohol Abuse 19 (1993):  153-8|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|Hedenmalm K "A case of severe withdrawal syndrome due to dextropropoxyphene." Ann Intern Med 123 (1995):  473|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27096, 0, 'Tapentadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27097, 0, 'Tapentadol', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27098, 0, 'Tapentadol', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27099, 0, 'Tapentadol', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27100, 0, 'Tapentadol', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27101, 0, 'Tapentadol', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27102, 0, 'Tapentadol', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27103, 0, 'Tapentadol', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27104, 16233, 'Temozolomide', 'Urticaria', 'Temozolomide is contraindicated in patients with a history of urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome.', '3', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27105, 16234, 'Temozolomide', 'Urticaria', 'Temozolomide is contraindicated in patients with a history of urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome.', '3', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27106, 27998, 'Temozolomide', 'Urticaria', 'Temozolomide is contraindicated in patients with a history of urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome.', '3', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27107, 27999, 'Temozolomide', 'Urticaria', 'Temozolomide is contraindicated in patients with a history of urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome.', '3', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27108, 28000, 'Temozolomide', 'Urticaria', 'Temozolomide is contraindicated in patients with a history of urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome.', '3', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27109, 28001, 'Temozolomide', 'Urticaria', 'Temozolomide is contraindicated in patients with a history of urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome.', '3', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27110, 28002, 'Temozolomide', 'Urticaria', 'Temozolomide is contraindicated in patients with a history of urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome.', '3', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27111, 28003, 'Temozolomide', 'Urticaria', 'Temozolomide is contraindicated in patients with a history of urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome.', '3', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27112, 16233, 'Temozolomide', 'Hepatic Insufficiency', 'A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in patients with normal hepatic function.  Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27113, 16234, 'Temozolomide', 'Hepatic Insufficiency', 'A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in patients with normal hepatic function.  Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27114, 27998, 'Temozolomide', 'Hepatic Insufficiency', 'A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in patients with normal hepatic function.  Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27115, 27999, 'Temozolomide', 'Hepatic Insufficiency', 'A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in patients with normal hepatic function.  Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27116, 28000, 'Temozolomide', 'Hepatic Insufficiency', 'A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in patients with normal hepatic function.  Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27117, 28001, 'Temozolomide', 'Hepatic Insufficiency', 'A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in patients with normal hepatic function.  Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27118, 28002, 'Temozolomide', 'Hepatic Insufficiency', 'A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in patients with normal hepatic function.  Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27119, 28003, 'Temozolomide', 'Hepatic Insufficiency', 'A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate hepatic impairment (Child-Pugh Class I - II) were similar to those observed in patients with normal hepatic function.  Caution should be exercised when temozolomide is administered to patients with severe hepatic impairment.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27120, 16233, 'Temozolomide', 'Bone Marrow Failure Disorders', 'Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.  Prior to dosing, patients must have an absolute neutrophil count (ANC) greater than or equal to 1.5  109/L and a platelet count greater than or equal to 100  109/L.  A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5  109/L and platelet count exceeds 100  109/L.  Therapy with temozolomide should be administered cautiously in patients with compromised bone marrow reserve.  Close clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27121, 16234, 'Temozolomide', 'Bone Marrow Failure Disorders', 'Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.  Prior to dosing, patients must have an absolute neutrophil count (ANC) greater than or equal to 1.5  109/L and a platelet count greater than or equal to 100  109/L.  A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5  109/L and platelet count exceeds 100  109/L.  Therapy with temozolomide should be administered cautiously in patients with compromised bone marrow reserve.  Close clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27122, 27998, 'Temozolomide', 'Bone Marrow Failure Disorders', 'Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.  Prior to dosing, patients must have an absolute neutrophil count (ANC) greater than or equal to 1.5  109/L and a platelet count greater than or equal to 100  109/L.  A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5  109/L and platelet count exceeds 100  109/L.  Therapy with temozolomide should be administered cautiously in patients with compromised bone marrow reserve.  Close clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27123, 27999, 'Temozolomide', 'Bone Marrow Failure Disorders', 'Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.  Prior to dosing, patients must have an absolute neutrophil count (ANC) greater than or equal to 1.5  109/L and a platelet count greater than or equal to 100  109/L.  A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5  109/L and platelet count exceeds 100  109/L.  Therapy with temozolomide should be administered cautiously in patients with compromised bone marrow reserve.  Close clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27124, 28000, 'Temozolomide', 'Bone Marrow Failure Disorders', 'Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.  Prior to dosing, patients must have an absolute neutrophil count (ANC) greater than or equal to 1.5  109/L and a platelet count greater than or equal to 100  109/L.  A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5  109/L and platelet count exceeds 100  109/L.  Therapy with temozolomide should be administered cautiously in patients with compromised bone marrow reserve.  Close clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27125, 28001, 'Temozolomide', 'Bone Marrow Failure Disorders', 'Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.  Prior to dosing, patients must have an absolute neutrophil count (ANC) greater than or equal to 1.5  109/L and a platelet count greater than or equal to 100  109/L.  A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5  109/L and platelet count exceeds 100  109/L.  Therapy with temozolomide should be administered cautiously in patients with compromised bone marrow reserve.  Close clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27126, 28002, 'Temozolomide', 'Bone Marrow Failure Disorders', 'Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.  Prior to dosing, patients must have an absolute neutrophil count (ANC) greater than or equal to 1.5  109/L and a platelet count greater than or equal to 100  109/L.  A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5  109/L and platelet count exceeds 100  109/L.  Therapy with temozolomide should be administered cautiously in patients with compromised bone marrow reserve.  Close clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27127, 28003, 'Temozolomide', 'Bone Marrow Failure Disorders', 'Patients treated with temozolomide may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.  Prior to dosing, patients must have an absolute neutrophil count (ANC) greater than or equal to 1.5  109/L and a platelet count greater than or equal to 100  109/L.  A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5  109/L and platelet count exceeds 100  109/L.  Therapy with temozolomide should be administered cautiously in patients with compromised bone marrow reserve.  Close clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27128, 16233, 'Temozolomide', 'Kidney Diseases', 'Temozolomide population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on its clearance after oral administration.  The pharmacokinetics of temozolomide have not been studied in patients with severely impaired renal function (CrCl <36 mL/min/m2).  Caution should be exercised when temozolomide is administered to patients with severe renal impairment.  Temozolomide has not been studied in patients on dialysis.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27129, 16234, 'Temozolomide', 'Kidney Diseases', 'Temozolomide population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on its clearance after oral administration.  The pharmacokinetics of temozolomide have not been studied in patients with severely impaired renal function (CrCl <36 mL/min/m2).  Caution should be exercised when temozolomide is administered to patients with severe renal impairment.  Temozolomide has not been studied in patients on dialysis.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27130, 27998, 'Temozolomide', 'Kidney Diseases', 'Temozolomide population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on its clearance after oral administration.  The pharmacokinetics of temozolomide have not been studied in patients with severely impaired renal function (CrCl <36 mL/min/m2).  Caution should be exercised when temozolomide is administered to patients with severe renal impairment.  Temozolomide has not been studied in patients on dialysis.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27131, 27999, 'Temozolomide', 'Kidney Diseases', 'Temozolomide population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on its clearance after oral administration.  The pharmacokinetics of temozolomide have not been studied in patients with severely impaired renal function (CrCl <36 mL/min/m2).  Caution should be exercised when temozolomide is administered to patients with severe renal impairment.  Temozolomide has not been studied in patients on dialysis.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27132, 28000, 'Temozolomide', 'Kidney Diseases', 'Temozolomide population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on its clearance after oral administration.  The pharmacokinetics of temozolomide have not been studied in patients with severely impaired renal function (CrCl <36 mL/min/m2).  Caution should be exercised when temozolomide is administered to patients with severe renal impairment.  Temozolomide has not been studied in patients on dialysis.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27133, 28001, 'Temozolomide', 'Kidney Diseases', 'Temozolomide population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on its clearance after oral administration.  The pharmacokinetics of temozolomide have not been studied in patients with severely impaired renal function (CrCl <36 mL/min/m2).  Caution should be exercised when temozolomide is administered to patients with severe renal impairment.  Temozolomide has not been studied in patients on dialysis.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27134, 28002, 'Temozolomide', 'Kidney Diseases', 'Temozolomide population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on its clearance after oral administration.  The pharmacokinetics of temozolomide have not been studied in patients with severely impaired renal function (CrCl <36 mL/min/m2).  Caution should be exercised when temozolomide is administered to patients with severe renal impairment.  Temozolomide has not been studied in patients on dialysis.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27135, 28003, 'Temozolomide', 'Kidney Diseases', 'Temozolomide population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on its clearance after oral administration.  The pharmacokinetics of temozolomide have not been studied in patients with severely impaired renal function (CrCl <36 mL/min/m2).  Caution should be exercised when temozolomide is administered to patients with severe renal impairment.  Temozolomide has not been studied in patients on dialysis.', '2', '"Product Information. Temodar (temozolomide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27136, 0, 'Temazepam', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|"Product Information. Onfi (clobazam)." Lundbeck Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27137, 0, 'Temazepam', 'Glaucoma, Angle-Closure', 'The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma.  These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.', '3', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27138, 0, 'Temazepam', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Onfi (clobazam)." Lundbeck Inc  (2011):|"Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27139, 0, 'Temazepam', 'Liver Diseases', 'Benzodiazepines are metabolized by the liver, and the metabolites are excreted in the urine.  Chlordiazepoxide, clorazepate, diazepam, flurazepam and quazepam undergo oxidative N-dealkylation to active metabolites that are substantially longer-acting than the parent compound.  These metabolites then undergo further biotransformation to pharmacologically inactive products before excretion by the kidney.  Therapy with benzodiazepines should be administered cautiously at lower initial dosages in patients with impaired renal and/or hepatic function.  Agents that are converted to weakly active, short-acting, or inactive metabolites may be preferable in hepatic impairment.  Lorazepam, oxazepam and temazepam are conjugated to inactive metabolites, while alprazolam, estazolam and triazolam undergo hydroxylation to weakly active or inactive metabolites.', '3', 'Sellers EM, Greenblatt DJ, Giles HG, et al. "Chlordiazepoxide and oxazepam disposition in cirrhosis." Clin Pharmacol Ther 26 (1979):  240-6|Hicks R, Dysken MW, Davis JM, et al. "The pharmacokinetics of psychotropic medication in the elderly: a review." J Clin Psychiatry 42 (1981):  374-85|Murray TG, Chiang ST, Koepke HH, Walker BR "Renal disease, age, and oxazepam kinetics." Clin Pharmacol Ther 30 (1981):  805-9|Hoyumpa AM "Disposition and elimination of minor tranquilizers in the aged and in patients with liver disease." South Med J 71 (1978):  23-8|Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR "Effects of age and liver disease on disposition of lorazepam." Clin Pharmacol Ther 24 (1978):  411-9|Verbeeck RK, Tjandramaga TB, de Schepper PJ, Verberckmoes R "Impaired elimination of lorazepam following subchronic administration in two patients with renal failure." Br J Clin Pharmacol 12 (1981):  749-50|Greenblatt DJ "Clinical pharmacokinetics of oxazepam and lorazepam." Clin Pharmacokinet 6 (1981):  89-105|Morrison G, Chiang ST, Koepke HH, Walker BR "Effect of renal impairment and hemodialysis on lorazepam kinetics." Clin Pharmacol Ther 35 (1984):  646-52|Klotz U, Avant GR, Hoyumpa A, Schenker S, Wikinson GR "The effects of age and liver disease on the disposition and elimination of diazepam in adult man." J Clin Invest 55 (1975):  347-59|Cutler RE, Blair AD "Pharmacokinetics of diazepam in normal and uremic humans." Clin Pharmacol Ther 25 (1979):  219-20|Ochs HR, Greenblatt DJ, Kaschell HJ, Klehr U, Divoll M, Abernathy DR "Diazepam kinetics in patients with renal insufficiency or hyperthyroidism." Br J Clin Pharmacol 12 (1981):  829-32|Schmith VD, Piraino B, Smith RB, Kroboth PD "Alprazolam in end-stage renal disease: I. Pharmacokinetics." J Clin Pharmacol 31 (1991):  571-9|Dehlin O, Kullingsjo H, Liden A, Agrell B, Moser G, Olsen I "Pharmacokinetics of alprazolam in geriatric patients with neurotic depression." Pharmacol Toxicol 68 (1991):  121-4|Sellers EM, Greenblatt DJ, Giles HG, et al. "Chlordiazepoxide and oxazepam disposition in cirrhosis." Clin Pharmacol Ther 26 (1979):  240-6|Morgan DD, Robinson JD, Mendenhall CL "Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis." Eur J Clin Pharmacol 19 (1981):  279-85|Tedesco FJ, Mills LR "Diazepam (valium) hepatitis." Dig Dis Sci 27 (1982):  470-2|de Silva JAF, Strojny N "Determination of flurazepam and its major biotransformation products in blood and urine by spectrophotofluorometry and spectrophotometry." J Pharm Sci 60 (1971):  1303-14|Kaplan SA, de Silva JAF, Jack ML, et al. "Blood level profile in man following chronic oral administration of flurazepam hydrochloride." J Pharm Sci 62 (1973):  1932-5|Greenblatt DJ, Divoll M, Harmatz JJ "Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs." Clin Pharmacol Ther 30 (1981):  475-86|Ghabrial H, Desmond PV, Watson KJ, et al. "The effects of age and chronic liver disease on the elimination of temazepam." Eur J Clin Pharmacol 30 (1986):  93-7|Busch U, Molzahn M, Bozler G, Koss FW "Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease." Arzneimittelforschung 31 (1981):  1507-11|Juhl RP, Van Thiel DH, Dittert LW, Smith RB "Alprazolam pharmacokinetics in alcoholic liver disease." J Clin Pharmacol 24 (1984):  113-9|Johnson J, Padilla BG, Carter J, Holt JH, Ozawa T "Adverse effects of flurazepam in a hemodialysis patient." J Am Assoc Nephrol Nurses Tech 4 (1977):  93-5|Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP "Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics." Clin Pharmacol Ther 37 (1985):  453-9|Wilensky AJ, Levy RH, Troupin AS, Moretti-Ojemann L "Clorazepate kinetics in treated epileptics." Clin Pharmacol Ther 24 (1978):  22-30|Greenblatt DJ, Divoll MK, Soong MH, Boxenbaum HG, Harmatz JS, Shader RI "Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam." J Clin Pharmacol 28 (1988):  853-9|Ochs HR, Rauh HW, Greenblatt DJ, Kaschell HJ "Clorazepate dipotassium and diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam." Nephron 37 (1984):  100-4|Roberts RK, Wilkinson GR, Branch RA, Schenker S "Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium)." Gastroenterology 75 (1978):  479-85|Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP "Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics." Br J Clin Pharmacol 19 (1985):  839-42|Kroboth PD, Smith RB, Van Thiel DH, Juhl RP "Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects." J Clin Pharmacol 27 (1987):  555-60|Hilbert JM, Chung M, Radwanski E, Gural R, Symchowicz S, Zampaglione N "Quazepam kinetics in the elderly." Clin Pharmacol Ther 36 (1984):  566-9|Chung M, Hilbert JM, Gural RP, Radwanski E, Symchowicz S, Zampaglione N "Multiple-dose quazepam kinetics." Clin Pharmacol Ther 35 (1984):  520-4|Gustavson LE, Carrigan PJ "The clinical pharmacokinetics of single doses of estazolam." Am J Med 88 (1990):  s2-5|Allen MD, Greenblatt DJ, Arnold JD "Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine." Psychopharmacology (Berl) 66 (1979):  267-74|"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27140, 0, 'Temazepam', 'Respiratory Insufficiency', 'Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with benzodiazepines should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.', '3', 'Iber FL, Livak A, Kruss DM "Apnea and cardiopulmonary arrest during and after endoscopy." J Clin Gastroenterol 14 (1992):  109-13|Cohen S, Khan A "Respiratory distress with use of lorazepam in mania." J Clin Psychopharmacol 7 (1987):  199-200|Donaldson D, Gibson G "System complications with intravenous diazepam." Oral Surg Oral Med Oral Patho 49 (1980):  126-30|Eldridge PR, Punt JA "Risks associated with giving benzodiazepines to patients with acute neurological injuries." Br Med J 300 (1990):  1189-90|Man GC, Hsu K, Sproule BJ "Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease." Chest 90 (1986):  832-6|Mendelson WB, Weingartner H, Greenblatt DJ, Garnett D, Gillin JC "A clinical study of flurazepam." Sleep 5 (1982):  350-60|"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|Pierce MW, Shu VS, Groves LJ "Safety of estazolam. The United States clinical experience." Am J Med 88 (1990):  s12-7|Skatrud JB, Badr S, Begle RL, Juan D "Ventilatory response to single, high dose estazolam in healthy humans." J Clin Pharmacol 30 (1990):  543-8|Sullivan RJ, Jr "Respiratory depression requiring ventilatory support following 0.5 mg of triazolam." J Am Geriatr Soc 37 (1989):  450-2|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|Model DG, Berry DJ "Effects of chlordiazepoxide in respiratory failure due to chronic bronchitis." Lancet 2 (1974):  869-70|Dixon D "Respiratory depression following midazolam." Anaesthesia 40 (1985):  922|Yakel DL, Jr  Whittaker SE, Elstad MR "Midazolam-induced angioedema and bronchoconstriction." Crit Care Med 20 (1992):  307-8|Berggren L, Eriksson I, Mollenholt P, Sunzel M "Changes in respiratory pattern after repeated doses of diazepam and midazolam in healthy subjects." Acta Anaesthesiol Scand 31 (1987):  667-72|Taylor JW, Simon KB "Possible intramuscular midazolam-associated cardiorespiratory arrest and death." DICP 24 (1990):  695-7|Munoz HR, Dagnino JA, Rufs JA, Bugedo GJ "Benzodiazepine premedication causes hypoxemia during spinal anesthesia in geriatric patients." Reg Anesth 17 (1992):  139-42|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|Murphy PJ, Erskine R, Langton JA "The effect of intravenously administered diazepam, midazolam and flumazenil on the sensitivity of upper airway reflexes." Anaesthesia 49 (1994):  105-10|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|Berry RB, Kouchi K, Bower J, Prosise G, Light RW "Triazolam in patients with obstructive sleep apnea." Am J Respir Crit Care Med 151 (1995):  450-4|"Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27141, 0, 'Temazepam', 'Seizures', 'The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal).  Appropriate anticonvulsant medication might need to be initiated or the dosage increased.  Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages.  Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy.  Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages.  Patients should be advised not to discontinue medication without first consulting with the physician.', '3', 'Ananth J "Abstinence syndrome from therapeutic doses of oxazepam." Can J Psychiatry 28 (1983):  592|Wilbur R, Kulik AV "Abstinence syndrome from therapeutic doses of oxazepam." Can J Psychiatry 28 (1983):  298-300|Busto U, Sellers EM, Naranjo CA, et al. "Withdrawal reaction after long-term therapeutic use of benzodiazepines." N Engl J Med 315 (1986):  854-9|Hersch EL, Billings RF "Acute confusional state with status petit mal as a withdrawal syndrome: and five year follow-up." Can J Psychiatry 33 (1988):  157-9|Howe JG "Lorazepam withdrawal seizures." Br Med J 280 (1980):  1163-4|Kales A, Bixler EO, Soldatos CR, Jacoby JA, Kales JD "Lorazepam: effects on sleep and withdrawal phenomena." Pharmacology 32 (1986):  121-30|Robinson GM, Sellers EM "Diazepam withdrawal seizures." Can Med Assoc J 126 (1982):  944-5|Browne JL, Hauge KJ "A review of alprazolam withdrawal." Drug Intell Clin Pharm 20 (1986):  837-41|Ghadirian AM, Gauthier S, Wong T "Convulsions in patients abruptly withdrawn from clonazepam while receiving neuroleptic medication ." Am J Psychiatry 144 (1987):  686|Hauser P, Devinsky O, De Bellis M, Theodore WH, Post RM "Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders." Arch Neurol 46 (1989):  696-9|Specht U, Boenigk HE, Wolf P "Discontinuation of clonazepam after long-term treatment." Epilepsia 30 (1989):  458-63|Alvarez N, Hartford E, Doubt C "Epileptic seizures induced by clonazepam." Clin Electroencephalogr 12 (1981):  57-65|Berlin RM, Conell LJ "Withdrawal symptoms after long-term treatment with therapeutic doses of flurazepam: a case report." Am J Psychiatry 140 (1983):  488-90|Bond WS, Schwartz M "Withdrawal reactions after long-term treatment with flurazepam." Clin Pharm 3 (1984):  316-8|"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|Tien AY, Gujavarty KS "Seizure following withdrawal from triazolam." Am J Psychiatry 142 (1985):  1516-7|Patterson WM "Triazolam withdrawal." J Clin Psychiatry 49 (1988):  369|Schneider LS, Syapin PJ, Pawluczyk S "Seizures following triazolam withdrawal despite benzodiazepine treatment." J Clin Psychiatry 48 (1987):  418-9|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|Ryan GP, Boisse NR "Experimental induction of benzodiazepine tolerance and physical dependence." J Pharmacol Exp Ther 226 (1983):  100-7|Petursson H, Lader MH "Benzodiazepine dependence." Br J Addict 76 (1981):  133-45|Finley PR, Nolan PE, Jr "Precipitation of benzodiazepine withdrawal following sudden discontinuation of midazolam." DICP 23 (1989):  151-2|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|Roy-Byrne PP, Sullivan MD, Cowley DS, Ries RK "Adjunctive treatment of benzodiazepine discontinuation syndromes - a review." J Psychiatr Res 27 Suppl (1993):  143-53|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|Frattola L, Garreau M, Piolti R, Bassi S, Albizzati MG, Borghi C, Morselli PL "Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients." Br J Psychiatry 165 (1994):  94-100', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27142, 0, 'Temazepam', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Onfi (clobazam)." Lundbeck Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27143, 0, 'Temazepam', 'Obesity', 'The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat.  Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam.  Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status.  Longer dosing intervals may be appropriate.  When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.', '2', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27144, 0, 'Temazepam', 'Psychotic Disorders', 'Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines.  The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.', '2', 'French AP "Dangerously aggressive behavior as a side effect of alprazolam." Am J Psychiatry 146 (1989):  276|Goodman WK, Charney DS "A case of alprazolam, but not lorazepam, inducing manic symptoms." J Clin Psychiatry 48 (1987):  117-8|Edwards JG, Inman WH, Pearce GL, Rawson NS "Prescription-event monitoring of 10,895 patients treated with alprazolam." Br J Psychiatry 158 (1991):  387-92|Wysowski DK, Barash D "Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration''s Spontaneous Reporting System." Arch Intern Med 151 (1991):  2003-8|Bixler EO, Kales A, Brubaker BH, Kales JD "Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system." Pharmacology 35 (1987):  286-300|Cohen LS, Rosenbaum JF "Clonazepam: new uses and potential problems." J Clin Psychiatry 48 (1987):  50-6|White MC, Silverman JJ, Harbison JW "Psychosis associated with clonazepam therapy for blepharospasm." J Nerv Ment Dis 170 (1982):  117-9|Dorevitch A "Mania associated with clonazepam." DICP 25 (1991):  938-9|Marchevsky S, Isaacs G, Nitzan I "Behavioral disinhibition with clonazepam." Gen Hosp Psychiatry 10 (1988):  447|Binder RL "Three case reports of behavioral disinhibition with clonazepam." Gen Hosp Psychiatry 9 (1987):  151-3|Koczerginski D, Kennedy SH, Swinson RP "Clonazepam and lithium--a toxic combination in the treatment of mania?" Int Clin Psychopharmacol 4 (1989):  195-9|Fava M, Borofsky GF "Sexual disinhibition during treatment with a benzodiazepine: a case report." Int J Psychiatry Med 21 (1991):  99-104|Cunningham TA "Letter: Adverse reaction to flurazepam." Can Med Assoc J 112 (1975):  805|Pollack MH "Clonazepam: a review of open clinical trials." J Clin Psychiatry 48 (1987):  12-5|"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|Karch FE "Rage reaction associated with clorazepate dipotassium." Ann Intern Med 91 (1979):  61-2|Weilburg JB, Sachs G, Falk WE "Triazolam-induced brief episodes of secondary mania in a depressed patient." J Clin Psychiatry 48 (1987):  492-3|Rothschild AJ "Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature." J Clin Psychiatry 53 (1992):  69-79|Schogt B, Conn D "Paranoid symptoms associated with triazolam." Can J Psychiatry 30 (1985):  462-3|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|Viscott DS "Chlordiazepoxide and hallucinations. Report of cases." Arch Gen Psychiatry 19 (1968):  370-6|Fiset L, Milgrom P, Beirne OR, Roy-Byrne P "Disinhibition of behaviors with midazolam: report of a case." J Oral Maxillofac Surg 50 (1992):  645-9|Lobo BL, Miwa LJ "Midazolam disinhibition reaction." Drug Intell Clin Pharm 22 (1988):  725|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|Rush CR, Higgins ST, Hughes JR, Bickel WK "A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers." Psychopharmacology (Berl) 112 (1993):  407-14|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27145, 0, 'Temazepam', 'Sleep Wake Disorders', 'Sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder.  The symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient.  The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric or medical illness that should be evaluated.  Worsening of insomnia with the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized disorder.', '2', '"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27146, 28355, 'Temsirolimus', 'Kidney Diseases', 'Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with inhibitors of mTOR (mammalian target of rapamycin).  Therapy with these agents should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function.  Renal impairment is not expected to influence drug exposure, and no dosage adjustment is recommended in patients with renal impairment.  Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27147, 28355, 'Temsirolimus', 'Peptic Ulcer Perforation', 'Cases of fatal bowel perforation occurred in patients who received temsirolimus.  Therapy with temsirolimus should be administered with caution in patients who may be at increased risk for gastrointestinal perforation, such as those with a history of diverticulitis.  Patients presenting with new onset or worsening of abdominal symptoms or blood in the stools should be evaluated promptly for early identification of gastrointestinal perforation.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27148, 28355, 'Temsirolimus', 'Hypersensitivity', 'Hypersensitivity/infusion reactions, including but not limited to flushing, chest pain, dyspnea, hypotension, apnea, loss of consciousness, hypersensitivity and anaphylaxis, have been associated with the administration of temsirolimus.  Caution should be exercised during the infusion and appropriate supportive care should be available.  For patients who develop hypersensitivity reaction during the infusion, it is recommended to stop the infusion and close observation with the possibility of resuming therapy at a slower rate should be contemplated at the discretion of the physician.  Temsirolimus infusion should be interrupted in all patients with severe infusion reactions and appropriate medical therapy administered.  A benefit-risk assessment should be done prior to the continuation of therapy in patients with severe or life-threatening reactions.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27149, 28355, 'Temsirolimus', 'Liver Diseases', 'Temsirolimus is contraindicated in patients with bilirubin >1.5ULN.  Caution is recommended when treating patients with mild hepatic impairment and a dose reduction may be needed depending on AST and bilirubin levels.  Dosage adjustment is needed based on hepatic function; therefore, assessment of AST and bilirubin levels is recommended before initiation of therapy and periodically thereafter.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27150, 28355, 'Temsirolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27151, 28355, 'Temsirolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27152, 28355, 'Temsirolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27153, 28355, 'Temsirolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27154, 0, 'Tenecteplase', 'Hemorrhage', 'The most common complication encountered during tenecteplase therapy is bleeding.  Tenecteplase therapy in patients with acute myocardial infarction is contraindicated in patients with active internal bleeding, history of cerebrovascular accident, intracranial or intraspinal surgery or trauma within 2 months, intracranial neoplasms, arteriovenous malformations or aneurysm, bleeding diathesis or severe uncontrolled hypertension, due to an increased risk of bleeding.  Each patient being considered for therapy should be carefully evaluated and anticipated benefits weighed against potential risks associated with therapy.', '3', '"Product Information. TNKase (tenecteplase)." Genentech  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27155, 0, 'Tenecteplase', 'Thromboembolism', 'The use of tenecteplase can increase the risk of thromboembolic events in patients with high likelihood of left heart thrombus, such as patients with mitral stenosis or atrial fibrillation.  Caution and monitoring is advised.', '2', '"Product Information. TNKase (tenecteplase)." Genentech  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27156, 0, 'Telavancin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27157, 0, 'Telavancin', 'Long QT Syndrome', 'Telavancin can cause QT prolongation, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  Use of telavancin should be avoided in patients with congenital long QT syndrome, known prolongation of the QTc interval, uncompensated heart failure, or severe left ventricular hypertrophy.', '3', '"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27158, 0, 'Telavancin', 'Hepatic Insufficiency', 'No dosage adjustment is recommended in patients with mild or moderate hepatic impairment.  The pharmacokinetics of telavancin have not been evaluated in patients with severe hepatic impairment.  Caution and close monitoring should be exercised when administering telavancin to patients with severe hepatic impairment.', '2', '"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27159, 0, 'Telavancin', 'Neurotoxicity Syndromes', 'Telavancin may increase the risk of nephrotoxicity in patients predisposed to kidney dysfunction (preexisting renal disease, diabetes mellitus, congestive heart failure, or hypertension) and in those taking medications known to affect kidney function.  It is recommended to monitor renal function (i.e., serum creatinine, creatinine clearance) prior to initiation of therapy, during treatment, and at the end of treatment in all patients receiving telavancin; and if renal function decreases, the benefit of continuing therapy versus discontinuing and initiating therapy with an alternative agent should be assessed.', '2', '"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27160, 0, 'Telavancin', 'Kidney Diseases', 'Use of telavancin in patients with preexisting moderate/severe renal impairment should be considered only when the anticipated benefit to the patient outweighs the potential risk.  Dosage adjustment is required in patients with <=50 mL/min renal impairment.  There is insufficient information to make specific dosage adjustment recommendations for patients with end-stage renal disease (CrCl <10 mL/min), including patients receiving hemodialysis.  Serum creatinine should be closely monitored and, if renal toxicity is suspected, an alternative agent should be considered.', '2', '"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27161, 233, 'Terbutaline', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977):  1-40|Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985):  840-7|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988):  850-5|Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981):  423-6|Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981):  402-4|Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982):  796-7|Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990):  762-3|Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985):  2068-72|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990):  1258|Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992):  501-6|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985):  6-21|Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993):  493-5|Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984):  367|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985):  443-9|Wagner JM, Morton MJ, Johnson KA, O''Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981):  2697-701|Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978):  2247|Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981):  195-200|Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973):  324-32|Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977):  76-80|Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986):  168-74|Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979):  229-36|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991):  895-912|Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982):  14-20|Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989):  309-15|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996):  183-91|Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981):  605-8|Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996):  1598-602|Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998):  1272-6|Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998):  380-7|Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998):  1081-2|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994):  209-16|Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996):  27-35|Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987):  533-9|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27162, 234, 'Terbutaline', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977):  1-40|Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985):  840-7|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988):  850-5|Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981):  423-6|Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981):  402-4|Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982):  796-7|Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990):  762-3|Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985):  2068-72|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990):  1258|Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992):  501-6|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985):  6-21|Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993):  493-5|Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984):  367|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985):  443-9|Wagner JM, Morton MJ, Johnson KA, O''Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981):  2697-701|Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978):  2247|Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981):  195-200|Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973):  324-32|Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977):  76-80|Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986):  168-74|Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979):  229-36|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991):  895-912|Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982):  14-20|Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989):  309-15|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996):  183-91|Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981):  605-8|Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996):  1598-602|Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998):  1272-6|Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998):  380-7|Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998):  1081-2|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994):  209-16|Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996):  27-35|Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987):  533-9|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27163, 1710, 'Terbutaline', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977):  1-40|Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985):  840-7|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988):  850-5|Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981):  423-6|Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981):  402-4|Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982):  796-7|Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990):  762-3|Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985):  2068-72|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990):  1258|Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992):  501-6|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985):  6-21|Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993):  493-5|Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984):  367|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985):  443-9|Wagner JM, Morton MJ, Johnson KA, O''Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981):  2697-701|Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978):  2247|Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981):  195-200|Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973):  324-32|Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977):  76-80|Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986):  168-74|Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979):  229-36|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991):  895-912|Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982):  14-20|Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989):  309-15|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996):  183-91|Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981):  605-8|Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996):  1598-602|Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998):  1272-6|Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998):  380-7|Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998):  1081-2|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994):  209-16|Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996):  27-35|Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987):  533-9|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27164, 1813, 'Terbutaline', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977):  1-40|Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985):  840-7|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988):  850-5|Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981):  423-6|Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981):  402-4|Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982):  796-7|Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990):  762-3|Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985):  2068-72|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990):  1258|Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992):  501-6|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985):  6-21|Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993):  493-5|Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984):  367|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985):  443-9|Wagner JM, Morton MJ, Johnson KA, O''Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981):  2697-701|Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978):  2247|Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981):  195-200|Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973):  324-32|Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977):  76-80|Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986):  168-74|Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979):  229-36|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991):  895-912|Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982):  14-20|Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989):  309-15|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996):  183-91|Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981):  605-8|Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996):  1598-602|Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998):  1272-6|Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998):  380-7|Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998):  1081-2|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994):  209-16|Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996):  27-35|Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987):  533-9|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27165, 15477, 'Terbutaline', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977):  1-40|Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985):  840-7|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988):  850-5|Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981):  423-6|Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981):  402-4|Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982):  796-7|Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990):  762-3|Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985):  2068-72|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990):  1258|Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992):  501-6|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985):  6-21|Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993):  493-5|Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984):  367|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985):  443-9|Wagner JM, Morton MJ, Johnson KA, O''Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981):  2697-701|Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978):  2247|Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981):  195-200|Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973):  324-32|Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977):  76-80|Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986):  168-74|Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979):  229-36|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991):  895-912|Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982):  14-20|Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989):  309-15|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996):  183-91|Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981):  605-8|Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996):  1598-602|Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998):  1272-6|Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998):  380-7|Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998):  1081-2|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994):  209-16|Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996):  27-35|Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987):  533-9|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27166, 28062, 'Terbutaline', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977):  1-40|Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985):  840-7|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988):  850-5|Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981):  423-6|Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981):  402-4|Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982):  796-7|Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990):  762-3|Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985):  2068-72|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990):  1258|Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992):  501-6|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985):  6-21|Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993):  493-5|Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984):  367|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985):  443-9|Wagner JM, Morton MJ, Johnson KA, O''Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981):  2697-701|Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978):  2247|Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981):  195-200|Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973):  324-32|Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977):  76-80|Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986):  168-74|Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979):  229-36|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991):  895-912|Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982):  14-20|Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989):  309-15|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996):  183-91|Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981):  605-8|Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996):  1598-602|Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998):  1272-6|Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998):  380-7|Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998):  1081-2|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994):  209-16|Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996):  27-35|Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987):  533-9|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27167, 28063, 'Terbutaline', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977):  1-40|Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985):  840-7|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988):  850-5|Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981):  423-6|Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981):  402-4|Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982):  796-7|Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990):  762-3|Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985):  2068-72|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990):  1258|Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992):  501-6|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985):  6-21|Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993):  493-5|Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984):  367|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985):  443-9|Wagner JM, Morton MJ, Johnson KA, O''Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981):  2697-701|Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978):  2247|Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981):  195-200|Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973):  324-32|Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977):  76-80|Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986):  168-74|Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979):  229-36|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991):  895-912|Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982):  14-20|Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989):  309-15|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996):  183-91|Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981):  605-8|Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996):  1598-602|Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998):  1272-6|Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998):  380-7|Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998):  1081-2|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994):  209-16|Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996):  27-35|Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987):  533-9|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27168, 233, 'Terbutaline', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27169, 234, 'Terbutaline', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27170, 1710, 'Terbutaline', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27171, 1813, 'Terbutaline', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27172, 15477, 'Terbutaline', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27173, 28062, 'Terbutaline', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27174, 28063, 'Terbutaline', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27175, 233, 'Terbutaline', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27176, 234, 'Terbutaline', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27177, 1710, 'Terbutaline', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27178, 1813, 'Terbutaline', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27179, 15477, 'Terbutaline', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27180, 28062, 'Terbutaline', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27181, 28063, 'Terbutaline', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27182, 233, 'Terbutaline', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27183, 234, 'Terbutaline', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27184, 1710, 'Terbutaline', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27185, 1813, 'Terbutaline', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27186, 15477, 'Terbutaline', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27187, 28062, 'Terbutaline', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27188, 28063, 'Terbutaline', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27189, 6681, 'Terazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27190, 6682, 'Terazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27191, 6681, 'Terazosin', 'Liver Diseases', 'Little data exist concerning the pharmacokinetic disposition of terazosin in patients with liver disease.  Terazosin is known to be metabolized by the liver, and both parent drug (approximately 30%) and metabolites are excreted in the bile and urine.  Therapy with terazosin should be administered cautiously in patients with significantly impaired hepatic function, since drug accumulation may occur.', '2', '"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27192, 6682, 'Terazosin', 'Liver Diseases', 'Little data exist concerning the pharmacokinetic disposition of terazosin in patients with liver disease.  Terazosin is known to be metabolized by the liver, and both parent drug (approximately 30%) and metabolites are excreted in the bile and urine.  Therapy with terazosin should be administered cautiously in patients with significantly impaired hepatic function, since drug accumulation may occur.', '2', '"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27193, 0, 'Teprotumumab', 'Diabetes Mellitus', 'The use of teprotumumab may increase blood glucose levels.  Care should be exercised when using this agent in patients with preexisting diabetes or impaired glucose tolerance and they should have appropriate glycemic control prior to initiating treatment.  It is recommended to monitor patients for elevated blood glucose and symptoms of hyperglycemia and to manage patients according to clinical guidelines.', '2', '"Product Information. Tepezza (teprotumumab)." Horizon Therapeutics USA Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27194, 0, 'Teprotumumab', 'Inflammatory Bowel Diseases', 'The use of teprotumumab may cause an exacerbation of preexisting inflammatory bowel disease (IBD).  Care should be exercised when using this agent in patients with IBD.  It is recommended to monitor patients for flare of disease and to consider treatment discontinuation if IBD exacerbation is suspected.', '2', '"Product Information. Tepezza (teprotumumab)." Horizon Therapeutics USA Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27195, 2546, 'Benazepril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27196, 2548, 'Benazepril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27197, 28765, 'Benazepril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27198, 28766, 'Benazepril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27199, 28767, 'Benazepril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27200, 2546, 'Benazepril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27201, 2548, 'Benazepril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27202, 28765, 'Benazepril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27203, 28766, 'Benazepril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27204, 28767, 'Benazepril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27205, 2546, 'Benazepril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27206, 2548, 'Benazepril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27207, 28765, 'Benazepril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27208, 28766, 'Benazepril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27209, 28767, 'Benazepril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27210, 2546, 'Benazepril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27211, 2548, 'Benazepril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27212, 28765, 'Benazepril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27213, 28766, 'Benazepril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27214, 28767, 'Benazepril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27215, 2546, 'Benazepril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27216, 2548, 'Benazepril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27217, 28765, 'Benazepril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27218, 28766, 'Benazepril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27219, 28767, 'Benazepril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27220, 2546, 'Benazepril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27221, 2548, 'Benazepril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27222, 28765, 'Benazepril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27223, 28766, 'Benazepril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27224, 28767, 'Benazepril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27225, 2546, 'Benazepril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27226, 2548, 'Benazepril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27227, 28765, 'Benazepril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27228, 28766, 'Benazepril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27229, 28767, 'Benazepril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27230, 2546, 'Benazepril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27231, 2548, 'Benazepril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27232, 28765, 'Benazepril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27233, 28766, 'Benazepril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27234, 28767, 'Benazepril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27235, 5392, 'Teriparatide', 'Hyperparathyroidism', 'Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):|"Product Information. Natpara (parathyroid hormone)." NPS Pharmaceuticals  (2015):|"Product Information. Tymlos (abaloparatide)." Radius Health  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27236, 19346, 'Teriparatide', 'Hyperparathyroidism', 'Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):|"Product Information. Natpara (parathyroid hormone)." NPS Pharmaceuticals  (2015):|"Product Information. Tymlos (abaloparatide)." Radius Health  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27237, 5392, 'Teriparatide', 'Neoplasms', 'Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma.  These agents should only be used if the potential benefits are considered to outweigh the potential risks.  Monitor these patients according to clinical guidelines.  Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):|"Product Information. Natpara (parathyroid hormone)." NPS Pharmaceuticals  (2015):|"Product Information. Tymlos (abaloparatide)." Radius Health  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27238, 19346, 'Teriparatide', 'Neoplasms', 'Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma.  These agents should only be used if the potential benefits are considered to outweigh the potential risks.  Monitor these patients according to clinical guidelines.  Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):|"Product Information. Natpara (parathyroid hormone)." NPS Pharmaceuticals  (2015):|"Product Information. Tymlos (abaloparatide)." Radius Health  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27239, 5392, 'Teriparatide', 'Osteoporosis', 'The use of teriparatide in patients with metabolic bone disease, other than osteoporosis is not recommended by the manufacturer.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27240, 19346, 'Teriparatide', 'Osteoporosis', 'The use of teriparatide in patients with metabolic bone disease, other than osteoporosis is not recommended by the manufacturer.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27241, 5392, 'Teriparatide', 'Hypotension, Orthostatic', 'There have been reports of transient episodes of symptomatic orthostatic hypotension with the use of teriparatide in short-term clinical pharmacology studies.  Caution is recommended when using this agent in patients at risk.', '2', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27242, 19346, 'Teriparatide', 'Hypotension, Orthostatic', 'There have been reports of transient episodes of symptomatic orthostatic hypotension with the use of teriparatide in short-term clinical pharmacology studies.  Caution is recommended when using this agent in patients at risk.', '2', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27243, 5392, 'Teriparatide', 'Kidney Diseases', 'No pharmacokinetic differences were identified in patients with mild or moderate renal impairment after a single dose of teriparatide.  In patients with severe renal impairment, the AUC and half-life of teriparatide were increased by 73% and 77%, respectively.  Care should be exercised in patients undergoing dialysis for chronic renal failure as no studies have been performed in this patient population.', '2', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27244, 19346, 'Teriparatide', 'Kidney Diseases', 'No pharmacokinetic differences were identified in patients with mild or moderate renal impairment after a single dose of teriparatide.  In patients with severe renal impairment, the AUC and half-life of teriparatide were increased by 73% and 77%, respectively.  Care should be exercised in patients undergoing dialysis for chronic renal failure as no studies have been performed in this patient population.', '2', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27245, 5392, 'Teriparatide', 'Urolithiasis', 'Teriparatide should be used with caution in patients with active urolithiasis.  If active or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered because of the potential to exacerbate urolithiasis in these patients.', '2', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27246, 19346, 'Teriparatide', 'Urolithiasis', 'Teriparatide should be used with caution in patients with active urolithiasis.  If active or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered because of the potential to exacerbate urolithiasis in these patients.', '2', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27247, 15060, 'Bendamustine', 'Hepatic Insufficiency', 'Bendamustine injection should be used with caution in patients with hepatic impairment.  Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.', '3', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27248, 15061, 'Bendamustine', 'Hepatic Insufficiency', 'Bendamustine injection should be used with caution in patients with hepatic impairment.  Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.', '3', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27249, 26065, 'Bendamustine', 'Hepatic Insufficiency', 'Bendamustine injection should be used with caution in patients with hepatic impairment.  Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.', '3', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27250, 26066, 'Bendamustine', 'Hepatic Insufficiency', 'Bendamustine injection should be used with caution in patients with hepatic impairment.  Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.', '3', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27251, 15060, 'Bendamustine', 'Kidney Diseases', 'Bendamustine injection should be used with caution in patients with mild or moderate renal impairment.  Bendamustine injection should not be used in patients with CrCL < 40 mL/min.', '3', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27252, 15061, 'Bendamustine', 'Kidney Diseases', 'Bendamustine injection should be used with caution in patients with mild or moderate renal impairment.  Bendamustine injection should not be used in patients with CrCL < 40 mL/min.', '3', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27253, 26065, 'Bendamustine', 'Kidney Diseases', 'Bendamustine injection should be used with caution in patients with mild or moderate renal impairment.  Bendamustine injection should not be used in patients with CrCL < 40 mL/min.', '3', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27254, 26066, 'Bendamustine', 'Kidney Diseases', 'Bendamustine injection should be used with caution in patients with mild or moderate renal impairment.  Bendamustine injection should not be used in patients with CrCL < 40 mL/min.', '3', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27255, 15060, 'Bendamustine', 'Infections', 'Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine.  Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections.  Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster.  It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection.  Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.', '2', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):|"Product Information. Bendeka (bendamustine)." Teva Pharmaceuticals USA  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27256, 15061, 'Bendamustine', 'Infections', 'Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine.  Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections.  Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster.  It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection.  Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.', '2', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):|"Product Information. Bendeka (bendamustine)." Teva Pharmaceuticals USA  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27257, 26065, 'Bendamustine', 'Infections', 'Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine.  Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections.  Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster.  It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection.  Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.', '2', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):|"Product Information. Bendeka (bendamustine)." Teva Pharmaceuticals USA  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27258, 26066, 'Bendamustine', 'Infections', 'Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine.  Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections.  Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster.  It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection.  Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.', '2', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):|"Product Information. Bendeka (bendamustine)." Teva Pharmaceuticals USA  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27259, 15060, 'Bendamustine', 'Bone Marrow Failure Disorders', 'Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death.  Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections.  Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.', '2', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27260, 15061, 'Bendamustine', 'Bone Marrow Failure Disorders', 'Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death.  Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections.  Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.', '2', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27261, 26065, 'Bendamustine', 'Bone Marrow Failure Disorders', 'Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death.  Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections.  Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.', '2', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27262, 26066, 'Bendamustine', 'Bone Marrow Failure Disorders', 'Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death.  Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections.  Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.', '2', '"Product Information. Treanda (bendamustine)." Cephalon Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27263, 151, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27264, 11330, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27265, 11336, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27266, 11338, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27267, 11339, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27268, 11340, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27269, 27721, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27270, 28086, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27271, 28087, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27272, 28088, 'Tetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27273, 151, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27274, 11330, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27275, 11336, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27276, 11338, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27277, 11339, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27278, 11340, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27279, 27721, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27280, 28086, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27281, 28087, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27282, 28088, 'Tetracycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27283, 151, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27284, 11330, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27285, 11336, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27286, 11338, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27287, 11339, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27288, 11340, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27289, 27721, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27290, 28086, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27291, 28087, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27292, 28088, 'Tetracycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972):  355-8|Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973):  318-24|Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974):  365-71|Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976):  24-31|Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978):  233-9|Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983):  245-52|Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963):  389-408|George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971):  1271-3|Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978):  223-36|Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981):  396|Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974):  299-308|Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975):  532-7|Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988):  355-66|Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977):  369-77|Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982):  137-45|Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973):  852-61|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985):  270-7|Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967):  433-5|Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980):  2513-5|Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978):  616|Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977):  52|Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977):  195-7|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27293, 151, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27294, 11330, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27295, 11336, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27296, 11338, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27297, 11339, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27298, 11340, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27299, 27721, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27300, 28086, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27301, 28087, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27302, 28088, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27303, 7196, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27304, 11072, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27305, 11073, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27306, 14146, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27307, 20022, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27308, 28077, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27309, 7196, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27310, 11072, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27311, 11073, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27312, 14146, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27313, 20022, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27314, 28077, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27315, 7196, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27316, 11072, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27317, 11073, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27318, 14146, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27319, 20022, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27320, 28077, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27321, 7196, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27322, 11072, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27323, 11073, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27324, 14146, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27325, 20022, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27326, 28077, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27327, 7196, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27328, 11072, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27329, 11073, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27330, 14146, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27331, 20022, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27332, 28077, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27333, 7196, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27334, 11072, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27335, 11073, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27336, 14146, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27337, 20022, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27338, 28077, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27339, 7196, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27340, 11072, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27341, 11073, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27342, 14146, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27343, 20022, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27344, 28077, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27345, 7196, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27346, 11072, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27347, 11073, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27348, 14146, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27349, 20022, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27350, 28077, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27351, 7196, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27352, 11072, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27353, 11073, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27354, 14146, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27355, 20022, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27356, 28077, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27357, 7196, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27358, 11072, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27359, 11073, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27360, 14146, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27361, 20022, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27362, 28077, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27363, 0, 'Tetrabenazine', 'Arrhythmias, Cardiac', 'Tetrabenazine can cause an increase in the corrected QT interval.  QT prolongation can lead to the development of ventricular arrhythmias.  The use of tetrabenazine should be avoided in patients with congenital long QT syndrome and in patients with a history of arrhythmias.', '3', '"Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27364, 0, 'Tetrabenazine', 'Depressive Disorder', 'The use of tetrabenazine is contraindicated in patients with untreated or uncontrolled depression.  Tetrabenazine can increase the risk of depression and suicidal thoughts and behavior.', '3', '"Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27365, 0, 'Tetrabenazine', 'Hepatic Insufficiency', 'The use of tetrabenazine is contraindicated in patients with hepatic impairment.  The safety and efficacy of exposure to the drug and other metabolites are unknown and it is not possible to adjust the dosage in hepatic impairment to ensure safe use.', '3', '"Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27366, 0, 'Tetrabenazine', 'Huntington Disease', 'Patients with Huntington disease are prone to depression.  Tetrabenazine can increase the risk of depression and suicidal thoughts and should be used with caution in patients with Huntington''s disease.  The benefits and risks of treatment should be considered before starting therapy, and patients should be under close observation for emergence or worsening of depression symptoms.  The family and caregivers should also be informed of this risk and should be instructed to report any changes in behavior or any concerns to the treating physician.', '3', '"Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27367, 0, 'Tetrabenazine', 'Deglutition Disorders', 'Tetrabenazine reduces dopaminergic transmission and can be associated with esophageal dysmotility and dysphagia.  Caution should be exercised when used in patients with conditions that predispose to dysphagia.  Special caution is advised in patients with Huntington''s disease as dysphagia is a common symptom and it could lead to aspiration pneumonia.', '2', '"Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27368, 0, 'Tetrabenazine', 'Hyperprolactinemia', 'Tetrabenazine can elevate serum prolactin concentrations.  This should be considered when therapy will be prescribed in patients with previously detected breast cancer.  Additionally, chronic increase in serum prolactin has been associated with low levels of estrogen and increase risk of osteoporosis.  If there is suspicion of hyperprolactinemia, appropriate laboratory testing is advised and treatment discontinuation should be considered.', '2', '"Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27369, 0, 'Tetrabenazine', 'Hypotension', 'Tetrabenazine can induce postural dizziness and syncope and should be used with caution in patients who are vulnerable to hypotension.', '2', '"Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27370, 0, 'Tesamorelin', 'Pituitary Neoplasms', 'The use of tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma and in patients with active malignancy.', '3', '"Product Information. Egrifta (tesamorelin)." Theratechnologies Inc.  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27371, 0, 'Tesamorelin', 'Diabetes Mellitus', 'The use of tesamorelin can result in glucose intolerance.  Tesamorelin increases insulin-like growth factor-1 (IGF-1).  It is recommended to evaluate glucose status prior to initiation of therapy and to monitor periodically during treatment.  Therapy discontinuation may be considered in patients that do not show a clear efficacy response and develop glucose intolerance or diabetes.  Diabetes patients should be monitored for potential development or worsening of retinopathy.  Care should be exercised when using this agent in patients with diabetes.', '2', '"Product Information. Egrifta (tesamorelin)." Theratechnologies Inc.  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27372, 0, 'Tesamorelin', 'Water-Electrolyte Imbalance', 'The use of tesamorelin may cause fluid retention related to the induction of growth hormone secretion.  This manifests as increased tissue turgor and musculoskeletal discomfort resulting in adverse reactions (e.g.  edema, arthralgia, and carpal tunnel syndrome) which are either transient or resolve with discontinuation of treatment.  Care should be exercised when using tesamorelin in patients at risks for fluid retention.', '2', '"Product Information. Egrifta (tesamorelin)." Theratechnologies Inc.  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27373, 5201, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27374, 5208, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27375, 5209, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27376, 5210, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27377, 5211, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27378, 5293, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27379, 5646, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27380, 7078, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27381, 7079, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27382, 7081, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27383, 7082, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27384, 7086, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27385, 11287, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27386, 11289, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27387, 13902, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27388, 21568, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27389, 21569, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27390, 21572, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27391, 21574, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27392, 23151, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27393, 23153, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27394, 28052, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27395, 28053, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27396, 28054, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27397, 28056, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27398, 28057, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27399, 28058, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27400, 28060, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27401, 28061, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27402, 28436, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27403, 28774, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27404, 28775, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', 'Lowe G, Green C, Jennings P "Hepatitis associated with terbinafine treatment." BMJ 306 (1993):  248|Balfour JA, Faulds D "Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses [published erratum appears in Drugs 1992 May;43(5):699]." Drugs 43 (1992):  259-84|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):|Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC "Terbinafine-induced cholestatic liver disease." J Hepatol 24 (1996):  753-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27405, 5201, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27406, 5208, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27407, 5209, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27408, 5210, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27409, 5211, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27410, 5293, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27411, 5646, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27412, 7078, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27413, 7079, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27414, 7081, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27415, 7082, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27416, 7086, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27417, 11287, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27418, 11289, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27419, 13902, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27420, 21568, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27421, 21569, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27422, 21572, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27423, 21574, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27424, 23151, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27425, 23153, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27426, 28052, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27427, 28053, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27428, 28054, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27429, 28056, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27430, 28057, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27431, 28058, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27432, 28060, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27433, 28061, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27434, 28436, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27435, 28774, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27436, 28775, 'Terbinafine', 'Neutropenia', 'Isolated cases of severe neutropenia have been reported in patients administered oral terbinafine.  A causal relationship has not been established, although the neutropenia resolved following discontinuation of terbinafine with or without supportive care.  Therapy with terbinafine should be administered cautiously in patients with preexisting neutropenia.  It may be appropriate to monitor blood counts more frequently during terbinafine therapy.  If secondary infection occurs and the neutrophil count is <= 1000 cells/mm3, terbinafine should be discontinued and supportive management initiated.', '3', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27437, 5201, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27438, 5208, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27439, 5209, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27440, 5210, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27441, 5211, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27442, 5293, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27443, 5646, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27444, 7078, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27445, 7079, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27446, 7081, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27447, 7082, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27448, 7086, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27449, 11287, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27450, 11289, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27451, 13902, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27452, 21568, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27453, 21569, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27454, 21572, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27455, 21574, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27456, 23151, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27457, 23153, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27458, 28052, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27459, 28053, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27460, 28054, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27461, 28056, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27462, 28057, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27463, 28058, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27464, 28060, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27465, 28061, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27466, 28436, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27467, 28774, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27468, 28775, 'Terbinafine', 'Depressive Disorder', 'Postmarketing studies have reported depressive symptoms with the use of terbinafine tablets.  Terbinafine should be used with caution in patients with depression, and prescribers should be alert to the development of depressive symptoms.  Patients and caregivers should be instructed to report any depressive symptoms.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27469, 5201, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27470, 5208, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27471, 5209, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27472, 5210, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27473, 5211, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27474, 5293, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27475, 5646, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27476, 7078, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27477, 7079, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27478, 7081, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27479, 7082, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27480, 7086, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27481, 11287, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27482, 11289, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27483, 13902, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27484, 21568, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27485, 21569, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27486, 21572, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27487, 21574, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27488, 23151, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27489, 23153, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27490, 28052, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27491, 28053, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27492, 28054, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27493, 28056, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27494, 28057, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27495, 28058, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27496, 28060, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27497, 28061, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27498, 28436, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27499, 28774, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27500, 28775, 'Terbinafine', 'IMMUNE SUPPRESSION', 'Transient decreases in absolute lymphocyte counts have been reported with oral terbinafine during clinical trials.  The clinical significance of these decreases is unknown.  Monitoring of complete blood counts may be appropriate in patients with known or suspected immunodeficiency receiving terbinafine for greater than six weeks.', '2', 'Kovacs MJ, Alshammari S, Guenther L, Bourcier M "Neutropenia and pancytopenia associated with oral terbinafine." J Am Acad Dermatol 31 (1994):  806|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27501, 5201, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27502, 5208, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27503, 5209, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27504, 5210, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27505, 5211, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27506, 5293, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27507, 5646, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27508, 7078, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27509, 7079, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27510, 7081, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27511, 7082, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27512, 7086, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27513, 11287, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27514, 11289, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27515, 13902, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27516, 21568, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27517, 21569, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27518, 21572, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27519, 21574, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27520, 23151, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27521, 23153, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27522, 28052, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27523, 28053, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27524, 28054, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27525, 28056, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27526, 28057, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27527, 28058, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27528, 28060, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27529, 28061, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27530, 28436, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27531, 28774, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27532, 28775, 'Terbinafine', 'Lupus Erythematosus, Systemic', 'Precipitation and exacerbation of cutaneous and systemic lupus erythematosus has been reported postmarketing in patients taking terbinafine tablets.  Terbinafine should be discontinued in patients with any clinical signs and symptoms suggestive of lupus erythematosus.', '2', '"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27533, 5201, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27534, 5208, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27535, 5209, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27536, 5210, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27537, 5211, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27538, 5293, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27539, 5646, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27540, 7078, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27541, 7079, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27542, 7081, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27543, 7082, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27544, 7086, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27545, 11287, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27546, 11289, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27547, 13902, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27548, 21568, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27549, 21569, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27550, 21572, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27551, 21574, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27552, 23151, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27553, 23153, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27554, 28052, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27555, 28053, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27556, 28054, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27557, 28056, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27558, 28057, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27559, 28058, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27560, 28060, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27561, 28061, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27562, 28436, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27563, 28774, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27564, 28775, 'Terbinafine', 'Kidney Diseases', 'The use of oral terbinafine in patients with renal impairment (CrCl <= 50 mL/min) has not been adequately studied and is, therefore, not recommended.  Terbinafine metabolites are primarily eliminated by the kidney.  The clinical significance of possible metabolite accumulation due to decreased clearance is unknown.', '2', 'Jensen JC "Clinical pharmacokinetics of terbinafine (Lamisil)." Clin Exp Dermatol 14 (1989):  110-3|"Product Information. Lamisil (terbinafine)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27565, 14611, 'Teriflunomide', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):|"Product Information. Gamifant (emapalumab)." Sobi Inc  (2018):|"Product Information. Lupkynis (voclosporin)." Aurinia Pharma  (2021):|"Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27566, 14611, 'Teriflunomide', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc  (2004):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27567, 14611, 'Teriflunomide', 'Liver Diseases', 'Teriflunomide is contraindicated in patients with severe hepatic impairment.  No dosage adjustment is necessary for patients with mild and moderate hepatic impairment.  Severe liver injury including fatal liver failure have been reported in patients treated with leflunomide.  A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.  Concomitant use of teriflunomide with other potentially hepatotoxic drugs may increase the risk of severe liver injury.  If drug-induced liver injury is suspected, discontinue therapy with teriflunomide and start an accelerated elimination procedure with cholestyramine or charcoal.  Patients with preexisting liver disease may be at increased risk of developing elevated serum transaminases while on therapy with teriflunomide.  It is recommended to obtain transaminase and bilirubin levels within 6 months before initiation of therapy.  Monitor ALT levels at least monthly for six months after starting therapy.', '3', '"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27568, 14611, 'Teriflunomide', 'Hypertension', 'Teriflunomide may increase the blood pressure.  Caution should be taken when using this agent in hypertensive patients.  It is recommended to check blood pressure before the start of teriflunomide treatment and periodically thereafter and elevated blood pressure should be appropriately managed during treatment with teriflunomide.', '2', '"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27569, 14611, 'Teriflunomide', 'IMMUNE SUPPRESSION', 'Cases of decrease in white blood cell count and in platelet count have been observed with the use teriflunomide.  Care should be taken when using this agent in immunosuppressed patients.  It is recommended to obtain a complete blood cell count within 6 months before the initiation of treatment and further monitoring should be based on signs and symptoms suggestive of bone marrow suppression.', '2', '"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27570, 14611, 'Teriflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy, including both polyneuropathy and mononeuropathy (e.g., carpal tunnel syndrome), has been reported with the use of teriflunomide.  Age older than 60 years, concomitant neurotoxic medications, and diabetes may increase the risk for peripheral neuropathy.  Care should be taken when prescribing this agent to patients at risk and if a patient develops symptoms consistent with peripheral neuropathy, such as bilateral numbness or tingling of hands or feet, consider discontinuing teriflunomide therapy and performing an accelerated elimination procedure.', '2', '"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27571, 14611, 'Teriflunomide', 'Lung Diseases, Interstitial', 'Interstitial lung disease and worsening of preexisting interstitial lung disease, including acute interstitial pneumonitis, have been reported during treatment with teriflunomide.  Caution should be exercised when prescribing this agent to patients with pulmonary complication.  New onset or worsening pulmonary symptoms, such as cough and dyspnea, with or without associated fever, may be a reason for discontinuation of therapy and if discontinuation of the drug is necessary, consider initiation of an accelerated elimination procedure.', '2', '"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27572, 14611, 'Teriflunomide', 'Tuberculosis', 'Cases of tuberculosis have been observed with the use of teriflunomide.  It is recommended to screen patients for latent tuberculosis infection before initiating therapy with teriflunomide.  The safety of teriflunomide in patients with a positive tuberculosis screen, and in individuals with latent tuberculosis infection is unknown.  Care should be exercised and in those patients testing positive, standard medical practice treatment should be given prior to teriflunomide therapy initiation.', '2', '"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27573, 0, 'Tetraferric tricitrate decahydrate', 'Hemochromatosis', 'The use of ferric citrate is contraindicated in patients with iron overload syndromes (e.g., hemochromatosis).  Iron absorption from the use of ferric citrate may lead to excessive elevations in iron stores.  Patients receiving intravenous iron may require a reduction in dose or discontinuation of treatment.  It is recommended to assess iron parameters before therapy with ferric citrate and monitor iron parameters while on treatment.', '3', '"Product Information. Auryxia (ferric citrate)." Keryx Biopharmaceuticals, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27574, 23204, 'Thalidomide', 'Seizures', 'Seizures, including grand mal convulsions, have been reported during post-approval use of thalidomide in clinical practice.  Because these events are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  Most patients had disorders that may have predisposed them to seizure activity, and it is not currently known whether thalidomide has any epileptogenic influence.  During therapy with thalidomide, patients with a history of seizures or with other risk factors for the development of seizures should be monitored closely for clinical changes that could precipitate acute seizure activity.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27575, 28097, 'Thalidomide', 'Seizures', 'Seizures, including grand mal convulsions, have been reported during post-approval use of thalidomide in clinical practice.  Because these events are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  Most patients had disorders that may have predisposed them to seizure activity, and it is not currently known whether thalidomide has any epileptogenic influence.  During therapy with thalidomide, patients with a history of seizures or with other risk factors for the development of seizures should be monitored closely for clinical changes that could precipitate acute seizure activity.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27576, 28098, 'Thalidomide', 'Seizures', 'Seizures, including grand mal convulsions, have been reported during post-approval use of thalidomide in clinical practice.  Because these events are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  Most patients had disorders that may have predisposed them to seizure activity, and it is not currently known whether thalidomide has any epileptogenic influence.  During therapy with thalidomide, patients with a history of seizures or with other risk factors for the development of seizures should be monitored closely for clinical changes that could precipitate acute seizure activity.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27577, 23204, 'Thalidomide', 'HIV Infections', 'In two separate studies involving HIV-seropositive patients, the use of thalidomide was associated with an increase in plasma viral RNA levels.  The clinical significance of this finding is unknown.  Both studies were published prior to the availability of highly active antiretroviral therapy, or HAART.  Until more information is available, the interim recommendation is to measure the viral load after the first and third months of thalidomide treatment and every 3 months thereafter (or as often as indicated by the patient''s antiretroviral regimen and clinical status).', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27578, 28097, 'Thalidomide', 'HIV Infections', 'In two separate studies involving HIV-seropositive patients, the use of thalidomide was associated with an increase in plasma viral RNA levels.  The clinical significance of this finding is unknown.  Both studies were published prior to the availability of highly active antiretroviral therapy, or HAART.  Until more information is available, the interim recommendation is to measure the viral load after the first and third months of thalidomide treatment and every 3 months thereafter (or as often as indicated by the patient''s antiretroviral regimen and clinical status).', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27579, 28098, 'Thalidomide', 'HIV Infections', 'In two separate studies involving HIV-seropositive patients, the use of thalidomide was associated with an increase in plasma viral RNA levels.  The clinical significance of this finding is unknown.  Both studies were published prior to the availability of highly active antiretroviral therapy, or HAART.  Until more information is available, the interim recommendation is to measure the viral load after the first and third months of thalidomide treatment and every 3 months thereafter (or as often as indicated by the patient''s antiretroviral regimen and clinical status).', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27580, 23204, 'Thalidomide', 'Hypotension', 'The use of thalidomide has been associated with dizziness and orthostatic hypotension.  Therapy with thalidomide should be administered cautiously in patients with preexisting hypotension.  Rising slowly from a recumbent position is recommended.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27581, 28097, 'Thalidomide', 'Hypotension', 'The use of thalidomide has been associated with dizziness and orthostatic hypotension.  Therapy with thalidomide should be administered cautiously in patients with preexisting hypotension.  Rising slowly from a recumbent position is recommended.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27582, 28098, 'Thalidomide', 'Hypotension', 'The use of thalidomide has been associated with dizziness and orthostatic hypotension.  Therapy with thalidomide should be administered cautiously in patients with preexisting hypotension.  Rising slowly from a recumbent position is recommended.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27583, 23204, 'Thalidomide', 'Neutropenia', 'The use of thalidomide has been associated with decreased white blood cells counts, including neutropenia.  Therapy with thalidomide should be administered cautiously in patients with preexisting neutropenia.  Treatment should not be initiated if absolute neutrophil count is below 750/mm3.  Monitoring white blood cell count and differential routinely is recommended during treatment.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27584, 28097, 'Thalidomide', 'Neutropenia', 'The use of thalidomide has been associated with decreased white blood cells counts, including neutropenia.  Therapy with thalidomide should be administered cautiously in patients with preexisting neutropenia.  Treatment should not be initiated if absolute neutrophil count is below 750/mm3.  Monitoring white blood cell count and differential routinely is recommended during treatment.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27585, 28098, 'Thalidomide', 'Neutropenia', 'The use of thalidomide has been associated with decreased white blood cells counts, including neutropenia.  Therapy with thalidomide should be administered cautiously in patients with preexisting neutropenia.  Treatment should not be initiated if absolute neutrophil count is below 750/mm3.  Monitoring white blood cell count and differential routinely is recommended during treatment.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27586, 23204, 'Thalidomide', 'Peripheral Nervous System Diseases', 'The use of thalidomide has been associated with the development of peripheral neuropathy, which is sometimes irreversible.  Therapy with thalidomide should be administered cautiously in patients with preexisting neuropathy and only after the neuropathy has returned to baseline.  Patients should be monitored routinely for early signs of neuropathy including numbness, tingling, pain, or a burning sensation in the hands or feet.  If symptoms of drug-induced neuropathy develop, thalidomide should be discontinued immediately.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27587, 28097, 'Thalidomide', 'Peripheral Nervous System Diseases', 'The use of thalidomide has been associated with the development of peripheral neuropathy, which is sometimes irreversible.  Therapy with thalidomide should be administered cautiously in patients with preexisting neuropathy and only after the neuropathy has returned to baseline.  Patients should be monitored routinely for early signs of neuropathy including numbness, tingling, pain, or a burning sensation in the hands or feet.  If symptoms of drug-induced neuropathy develop, thalidomide should be discontinued immediately.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27588, 28098, 'Thalidomide', 'Peripheral Nervous System Diseases', 'The use of thalidomide has been associated with the development of peripheral neuropathy, which is sometimes irreversible.  Therapy with thalidomide should be administered cautiously in patients with preexisting neuropathy and only after the neuropathy has returned to baseline.  Patients should be monitored routinely for early signs of neuropathy including numbness, tingling, pain, or a burning sensation in the hands or feet.  If symptoms of drug-induced neuropathy develop, thalidomide should be discontinued immediately.', '2', '"Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27589, 11105, 'Tetracosactide', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of adrenocorticotropic agents may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if adrenocorticotropic therapy is administered to these patients.  During prolonged use, tuberculosis chemoprophylaxis may be considered.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27590, 13507, 'Tetracosactide', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of adrenocorticotropic agents may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if adrenocorticotropic therapy is administered to these patients.  During prolonged use, tuberculosis chemoprophylaxis may be considered.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27591, 11105, 'Tetracosactide', 'Adrenal Insufficiency', 'The use of adrenocorticotropic agents is contraindicated in patients with primary adrenocortical insufficiency because of the lack of adrenal responsiveness.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27592, 13507, 'Tetracosactide', 'Adrenal Insufficiency', 'The use of adrenocorticotropic agents is contraindicated in patients with primary adrenocortical insufficiency because of the lack of adrenal responsiveness.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27593, 11105, 'Tetracosactide', 'Water-Electrolyte Imbalance', 'Adrenocorticotropic agents may cause hypernatremia, hypokalemia, hypocalcemia, and fluid retention.  Therapy with these agents, particularly if intended for longer than brief periods, should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27594, 13507, 'Tetracosactide', 'Water-Electrolyte Imbalance', 'Adrenocorticotropic agents may cause hypernatremia, hypokalemia, hypocalcemia, and fluid retention.  Therapy with these agents, particularly if intended for longer than brief periods, should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27595, 11105, 'Tetracosactide', 'Peptic Ulcer Perforation', 'Adrenocorticotropic agents may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with adrenocorticotropic agents should be administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27596, 13507, 'Tetracosactide', 'Peptic Ulcer Perforation', 'Adrenocorticotropic agents may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with adrenocorticotropic agents should be administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27597, 11105, 'Tetracosactide', 'Adrenocortical Hyperfunction', 'The use of adrenocorticotropic agents is contraindicated in patients with adrenocortical hyperfunction.  These agents stimulate the release of cortisol and aldosterone and may aggravate symptoms of hyperadrenocorticism.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27598, 13507, 'Tetracosactide', 'Adrenocortical Hyperfunction', 'The use of adrenocorticotropic agents is contraindicated in patients with adrenocortical hyperfunction.  These agents stimulate the release of cortisol and aldosterone and may aggravate symptoms of hyperadrenocorticism.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27599, 11105, 'Tetracosactide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of adrenocorticotropic agents, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, adrenocorticotropic agents should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  For patients who have received prolonged adrenocorticotropic therapy who develop a severe or life-threatening infection, supplemental doses of rapid-acting corticosteroids may be required, since these patients may have hypothalamic-pituitary insufficiency.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27600, 13507, 'Tetracosactide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of adrenocorticotropic agents, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, adrenocorticotropic agents should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  For patients who have received prolonged adrenocorticotropic therapy who develop a severe or life-threatening infection, supplemental doses of rapid-acting corticosteroids may be required, since these patients may have hypothalamic-pituitary insufficiency.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27601, 11105, 'Tetracosactide', 'Keratitis, Herpetic', 'Adrenocorticotropic agents should be used cautiously, if at all, in patients with ocular herpes simplex because of the risk of corneal perforation.  The manufacturers consider their use to be contraindicated in such setting.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27602, 13507, 'Tetracosactide', 'Keratitis, Herpetic', 'Adrenocorticotropic agents should be used cautiously, if at all, in patients with ocular herpes simplex because of the risk of corneal perforation.  The manufacturers consider their use to be contraindicated in such setting.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27603, 11105, 'Tetracosactide', 'Osteoporosis', 'Adrenocorticotropic agents inhibit the absorption of intestinal calcium and increase urinary excretion of calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of these agents, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose adrenocorticotropic therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  The manufacturers consider the use of adrenocorticotropic agents to be contraindicated in such setting.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27604, 13507, 'Tetracosactide', 'Osteoporosis', 'Adrenocorticotropic agents inhibit the absorption of intestinal calcium and increase urinary excretion of calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of these agents, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose adrenocorticotropic therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  The manufacturers consider the use of adrenocorticotropic agents to be contraindicated in such setting.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27605, 11105, 'Tetracosactide', 'Peptic Ulcer', 'Adrenocorticotropic agents may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  Delayed healing of peptic ulcers has also been reported.  Therapy with adrenocorticotropic agents, if necessary, should be administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  The manufacturers consider their use to be contraindicated in such setting.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27606, 13507, 'Tetracosactide', 'Peptic Ulcer', 'Adrenocorticotropic agents may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  Delayed healing of peptic ulcers has also been reported.  Therapy with adrenocorticotropic agents, if necessary, should be administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  The manufacturers consider their use to be contraindicated in such setting.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27607, 11105, 'Tetracosactide', 'Scleroderma, Localized', 'The use of adrenocorticotropic agents is contraindicated in patients with scleroderma.  Adrenocorticotropic agents may precipitate renal crisis with malignant hypertension in these patients, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  If treatment is required for inflammatory myositis or pericarditis, glucocorticoids are preferable because of their more predictable pharmacologic effect.  However, glucocorticoids should also be avoided in the long-term treatment of patients with scleroderma for similar reasons.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27608, 13507, 'Tetracosactide', 'Scleroderma, Localized', 'The use of adrenocorticotropic agents is contraindicated in patients with scleroderma.  Adrenocorticotropic agents may precipitate renal crisis with malignant hypertension in these patients, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  If treatment is required for inflammatory myositis or pericarditis, glucocorticoids are preferable because of their more predictable pharmacologic effect.  However, glucocorticoids should also be avoided in the long-term treatment of patients with scleroderma for similar reasons.', '3', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27609, 11105, 'Tetracosactide', 'Fibrosis', 'Adrenocorticotropic agents may have enhanced effects in patients with cirrhosis.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27610, 13507, 'Tetracosactide', 'Fibrosis', 'Adrenocorticotropic agents may have enhanced effects in patients with cirrhosis.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27611, 11105, 'Tetracosactide', 'Psychotic Disorders', 'Adrenocorticotropic agents may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during adrenocorticotropic therapy.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27612, 13507, 'Tetracosactide', 'Psychotic Disorders', 'Adrenocorticotropic agents may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during adrenocorticotropic therapy.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27613, 11105, 'Tetracosactide', 'Diabetes Mellitus', 'Adrenocorticotropic agents may impair glucose tolerance and cause hyperglycemia.  Therapy with these agents should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during adrenocorticotropic therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27614, 13507, 'Tetracosactide', 'Diabetes Mellitus', 'Adrenocorticotropic agents may impair glucose tolerance and cause hyperglycemia.  Therapy with these agents should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during adrenocorticotropic therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27615, 11105, 'Tetracosactide', 'Ocular Hypertension', 'Prolonged use of adrenocorticotropic agents may cause elevated intraocular pressure and glaucoma with possible damage to the optic nerves.  Long-term therapy with these agents should be administered cautiously in patients with preexisting glaucoma (particularly open-angle glaucoma) or increased intraocular pressure.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27616, 13507, 'Tetracosactide', 'Ocular Hypertension', 'Prolonged use of adrenocorticotropic agents may cause elevated intraocular pressure and glaucoma with possible damage to the optic nerves.  Long-term therapy with these agents should be administered cautiously in patients with preexisting glaucoma (particularly open-angle glaucoma) or increased intraocular pressure.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27617, 11105, 'Tetracosactide', 'Hypothyroidism', 'Adrenocorticotropic agents may have enhanced effects in patients with hypothyroidism.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27618, 13507, 'Tetracosactide', 'Hypothyroidism', 'Adrenocorticotropic agents may have enhanced effects in patients with hypothyroidism.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27619, 11105, 'Tetracosactide', 'Myasthenia Gravis', 'While corticotropin has been used effectively in severe, refractory myasthenia gravis to increase muscle strength, it should nevertheless be administered with extreme caution in such setting.  Patients must be treated in an intensive care unit and receive respiratory support, since muscle strength will markedly decrease initially.  Improvement usually occurs several days after the first or second course of treatment.  Similar responses might be expected of other adrenocorticotropic agents, although their use in myasthenia gravis has not been studied extensively.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27620, 13507, 'Tetracosactide', 'Myasthenia Gravis', 'While corticotropin has been used effectively in severe, refractory myasthenia gravis to increase muscle strength, it should nevertheless be administered with extreme caution in such setting.  Patients must be treated in an intensive care unit and receive respiratory support, since muscle strength will markedly decrease initially.  Improvement usually occurs several days after the first or second course of treatment.  Similar responses might be expected of other adrenocorticotropic agents, although their use in myasthenia gravis has not been studied extensively.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27621, 11105, 'Tetracosactide', 'Muscular Diseases', 'Toxic myopathy may occur with the prolonged use of adrenocorticotropic agents, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadraparesis.  Elevations of creatine kinase may also occur, albeit infrequently.  After withdrawal of ACTH therapy, recovery may be slow and incomplete.  Therapy with adrenocorticotropic agents should be administered cautiously in patients with preexisting myopathy or myoneural disorders, since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal or no changes of myopathy on EMG, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of adrenocorticotropic therapy should be considered.', '2', 'Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27622, 13507, 'Tetracosactide', 'Muscular Diseases', 'Toxic myopathy may occur with the prolonged use of adrenocorticotropic agents, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadraparesis.  Elevations of creatine kinase may also occur, albeit infrequently.  After withdrawal of ACTH therapy, recovery may be slow and incomplete.  Therapy with adrenocorticotropic agents should be administered cautiously in patients with preexisting myopathy or myoneural disorders, since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal or no changes of myopathy on EMG, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of adrenocorticotropic therapy should be considered.', '2', 'Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27623, 11105, 'Tetracosactide', 'Thromboembolism', 'Adrenocorticotropic agents may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  These agents should be used cautiously in patients with thrombotic or thromboembolic disorders.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27624, 13507, 'Tetracosactide', 'Thromboembolism', 'Adrenocorticotropic agents may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  These agents should be used cautiously in patients with thrombotic or thromboembolic disorders.', '2', '"Product Information. Acthar (corticotropin)." Rhone Poulenc Rorer  (2001):|"Product Information. Acthrel (corticorelin)." Ferring Pharmaceuticals Inc  (2001):|"Product Information. Cortrosyn (cosyntropin)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27625, 684, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27626, 8210, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27627, 11348, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27628, 11349, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27629, 11354, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27630, 11909, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27631, 12208, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27632, 12209, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27633, 14071, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27634, 16323, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27635, 25546, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27636, 25547, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27637, 28102, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27638, 28105, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27639, 28106, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27640, 28107, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27641, 28108, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27642, 28745, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27643, 29717, 'Theophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27644, 684, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27645, 8210, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27646, 11348, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27647, 11349, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27648, 11354, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27649, 11909, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27650, 12208, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27651, 12209, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27652, 14071, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27653, 16323, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27654, 25546, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27655, 25547, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27656, 28102, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27657, 28105, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27658, 28106, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27659, 28107, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27660, 28108, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27661, 28745, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27662, 29717, 'Theophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27663, 684, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27664, 8210, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27665, 11348, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27666, 11349, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27667, 11354, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27668, 11909, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27669, 12208, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27670, 12209, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27671, 14071, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27672, 16323, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27673, 25546, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27674, 25547, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27675, 28102, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27676, 28105, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27677, 28106, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27678, 28107, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27679, 28108, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27680, 28745, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27681, 29717, 'Theophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27682, 684, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27683, 8210, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27684, 11348, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27685, 11349, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27686, 11354, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27687, 11909, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27688, 12208, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27689, 12209, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27690, 14071, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27691, 16323, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27692, 25546, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27693, 25547, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27694, 28102, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27695, 28105, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27696, 28106, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27697, 28107, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27698, 28108, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27699, 28745, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27700, 29717, 'Theophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27701, 684, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27702, 8210, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27703, 11348, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27704, 11349, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27705, 11354, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27706, 11909, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27707, 12208, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27708, 12209, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27709, 14071, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27710, 16323, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27711, 25546, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27712, 25547, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27713, 28102, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27714, 28105, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27715, 28106, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27716, 28107, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27717, 28108, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27718, 28745, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27719, 29717, 'Theophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27720, 684, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27721, 8210, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27722, 11348, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27723, 11349, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27724, 11354, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27725, 11909, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27726, 12208, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27727, 12209, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27728, 14071, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27729, 16323, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27730, 25546, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27731, 25547, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27732, 28102, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27733, 28105, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27734, 28106, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27735, 28107, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27736, 28108, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27737, 28745, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27738, 29717, 'Theophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27739, 718, 'Thiopental', 'Addison Disease', 'Thiopental should not be used in patients with Addison disease or any adrenal gland disorder.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27740, 28125, 'Thiopental', 'Addison Disease', 'Thiopental should not be used in patients with Addison disease or any adrenal gland disorder.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27741, 28127, 'Thiopental', 'Addison Disease', 'Thiopental should not be used in patients with Addison disease or any adrenal gland disorder.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27742, 28128, 'Thiopental', 'Addison Disease', 'Thiopental should not be used in patients with Addison disease or any adrenal gland disorder.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27743, 28129, 'Thiopental', 'Addison Disease', 'Thiopental should not be used in patients with Addison disease or any adrenal gland disorder.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27744, 28130, 'Thiopental', 'Addison Disease', 'Thiopental should not be used in patients with Addison disease or any adrenal gland disorder.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27745, 718, 'Thiopental', 'Asthma', 'Thiopental should not be used in patients with asthma as it can lead to intraoperative bronchospasm which can be catastrophic.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27746, 28125, 'Thiopental', 'Asthma', 'Thiopental should not be used in patients with asthma as it can lead to intraoperative bronchospasm which can be catastrophic.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27747, 28127, 'Thiopental', 'Asthma', 'Thiopental should not be used in patients with asthma as it can lead to intraoperative bronchospasm which can be catastrophic.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27748, 28128, 'Thiopental', 'Asthma', 'Thiopental should not be used in patients with asthma as it can lead to intraoperative bronchospasm which can be catastrophic.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27749, 28129, 'Thiopental', 'Asthma', 'Thiopental should not be used in patients with asthma as it can lead to intraoperative bronchospasm which can be catastrophic.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27750, 28130, 'Thiopental', 'Asthma', 'Thiopental should not be used in patients with asthma as it can lead to intraoperative bronchospasm which can be catastrophic.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27751, 718, 'Thiopental', 'Liver Diseases', 'Thiopental should not be used in patients with liver dysfunction.  The distribution half-life and the duration of the drug action will be prolonged.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27752, 28125, 'Thiopental', 'Liver Diseases', 'Thiopental should not be used in patients with liver dysfunction.  The distribution half-life and the duration of the drug action will be prolonged.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27753, 28127, 'Thiopental', 'Liver Diseases', 'Thiopental should not be used in patients with liver dysfunction.  The distribution half-life and the duration of the drug action will be prolonged.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27754, 28128, 'Thiopental', 'Liver Diseases', 'Thiopental should not be used in patients with liver dysfunction.  The distribution half-life and the duration of the drug action will be prolonged.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27755, 28129, 'Thiopental', 'Liver Diseases', 'Thiopental should not be used in patients with liver dysfunction.  The distribution half-life and the duration of the drug action will be prolonged.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27756, 28130, 'Thiopental', 'Liver Diseases', 'Thiopental should not be used in patients with liver dysfunction.  The distribution half-life and the duration of the drug action will be prolonged.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27757, 718, 'Thiopental', 'Myasthenia Gravis', 'Thiopental should not be used in patients with myasthenia gravis as it can prompt myasthenic crises.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27758, 28125, 'Thiopental', 'Myasthenia Gravis', 'Thiopental should not be used in patients with myasthenia gravis as it can prompt myasthenic crises.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27759, 28127, 'Thiopental', 'Myasthenia Gravis', 'Thiopental should not be used in patients with myasthenia gravis as it can prompt myasthenic crises.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27760, 28128, 'Thiopental', 'Myasthenia Gravis', 'Thiopental should not be used in patients with myasthenia gravis as it can prompt myasthenic crises.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27761, 28129, 'Thiopental', 'Myasthenia Gravis', 'Thiopental should not be used in patients with myasthenia gravis as it can prompt myasthenic crises.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27762, 28130, 'Thiopental', 'Myasthenia Gravis', 'Thiopental should not be used in patients with myasthenia gravis as it can prompt myasthenic crises.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27763, 718, 'Thiopental', 'Porphyrias', 'The use of thiopental is contraindicated in patients with porphyria.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27764, 28125, 'Thiopental', 'Porphyrias', 'The use of thiopental is contraindicated in patients with porphyria.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27765, 28127, 'Thiopental', 'Porphyrias', 'The use of thiopental is contraindicated in patients with porphyria.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27766, 28128, 'Thiopental', 'Porphyrias', 'The use of thiopental is contraindicated in patients with porphyria.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27767, 28129, 'Thiopental', 'Porphyrias', 'The use of thiopental is contraindicated in patients with porphyria.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27768, 28130, 'Thiopental', 'Porphyrias', 'The use of thiopental is contraindicated in patients with porphyria.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27769, 718, 'Thiopental', 'Kidney Diseases', 'Thiopental should not be used in patients with renal impairment.  If so, the dose needs to be considerably reduced.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27770, 28125, 'Thiopental', 'Kidney Diseases', 'Thiopental should not be used in patients with renal impairment.  If so, the dose needs to be considerably reduced.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27771, 28127, 'Thiopental', 'Kidney Diseases', 'Thiopental should not be used in patients with renal impairment.  If so, the dose needs to be considerably reduced.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27772, 28128, 'Thiopental', 'Kidney Diseases', 'Thiopental should not be used in patients with renal impairment.  If so, the dose needs to be considerably reduced.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27773, 28129, 'Thiopental', 'Kidney Diseases', 'Thiopental should not be used in patients with renal impairment.  If so, the dose needs to be considerably reduced.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27774, 28130, 'Thiopental', 'Kidney Diseases', 'Thiopental should not be used in patients with renal impairment.  If so, the dose needs to be considerably reduced.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27775, 718, 'Thiopental', 'Anemia', 'Thiopental should not be used in patients with severe anemia.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27776, 28125, 'Thiopental', 'Anemia', 'Thiopental should not be used in patients with severe anemia.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27777, 28127, 'Thiopental', 'Anemia', 'Thiopental should not be used in patients with severe anemia.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27778, 28128, 'Thiopental', 'Anemia', 'Thiopental should not be used in patients with severe anemia.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27779, 28129, 'Thiopental', 'Anemia', 'Thiopental should not be used in patients with severe anemia.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27780, 28130, 'Thiopental', 'Anemia', 'Thiopental should not be used in patients with severe anemia.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27781, 718, 'Thiopental', 'Thyroid Diseases', 'Thiopental should not be used in patients with thyroid disorder as it influences thyroid metabolism.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27782, 28125, 'Thiopental', 'Thyroid Diseases', 'Thiopental should not be used in patients with thyroid disorder as it influences thyroid metabolism.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27783, 28127, 'Thiopental', 'Thyroid Diseases', 'Thiopental should not be used in patients with thyroid disorder as it influences thyroid metabolism.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27784, 28128, 'Thiopental', 'Thyroid Diseases', 'Thiopental should not be used in patients with thyroid disorder as it influences thyroid metabolism.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27785, 28129, 'Thiopental', 'Thyroid Diseases', 'Thiopental should not be used in patients with thyroid disorder as it influences thyroid metabolism.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27786, 28130, 'Thiopental', 'Thyroid Diseases', 'Thiopental should not be used in patients with thyroid disorder as it influences thyroid metabolism.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27787, 11385, 'Thioridazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27788, 28140, 'Thioridazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27789, 28141, 'Thioridazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27790, 11385, 'Thioridazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27791, 28140, 'Thioridazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27792, 28141, 'Thioridazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27793, 11385, 'Thioridazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27794, 28140, 'Thioridazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27795, 28141, 'Thioridazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27796, 11385, 'Thioridazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27797, 28140, 'Thioridazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27798, 28141, 'Thioridazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27799, 11385, 'Thioridazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27800, 28140, 'Thioridazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27801, 28141, 'Thioridazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27802, 11385, 'Thioridazine', 'Long QT Syndrome', 'The use of thioridazine is contraindicated in patients with congenital or acquired QT interval prolongation syndromes or a history of cardiac arrhythmias.  Thioridazine can prolong the QT interval of the electrocardiogram in a dose-related manner.  The risk of torsade de pointes is progressively increased as the degree of prolongation becomes greater.  In a crossover study of nine patients, a single 50 mg dose of thioridazine increased the QTc interval by a mean maximum of 23 msec compared to placebo.  During postmarketing experience, torsade de pointes and sudden death have been reported, although a causal relationship has not been determined.  The manufacturer states that thioridazine should not be administered in patients with a baseline QTc interval greater than 450 msec, and that it should be discontinued in patients with QTc measurements exceeding 500 msec during therapy.  Electrolyte disturbances such as hypokalemia and hypomagnesemia may augment the prolongation effect of thioridazine on the QT interval and should be corrected prior to institution of therapy.  Patients who experience frequent, severe, or prolonged diarrhea may be subject to electrolyte losses and should be followed closely and managed accordingly during therapy with thioridazine.', '3', 'Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001):  1774-82', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27803, 28140, 'Thioridazine', 'Long QT Syndrome', 'The use of thioridazine is contraindicated in patients with congenital or acquired QT interval prolongation syndromes or a history of cardiac arrhythmias.  Thioridazine can prolong the QT interval of the electrocardiogram in a dose-related manner.  The risk of torsade de pointes is progressively increased as the degree of prolongation becomes greater.  In a crossover study of nine patients, a single 50 mg dose of thioridazine increased the QTc interval by a mean maximum of 23 msec compared to placebo.  During postmarketing experience, torsade de pointes and sudden death have been reported, although a causal relationship has not been determined.  The manufacturer states that thioridazine should not be administered in patients with a baseline QTc interval greater than 450 msec, and that it should be discontinued in patients with QTc measurements exceeding 500 msec during therapy.  Electrolyte disturbances such as hypokalemia and hypomagnesemia may augment the prolongation effect of thioridazine on the QT interval and should be corrected prior to institution of therapy.  Patients who experience frequent, severe, or prolonged diarrhea may be subject to electrolyte losses and should be followed closely and managed accordingly during therapy with thioridazine.', '3', 'Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001):  1774-82', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27804, 28141, 'Thioridazine', 'Long QT Syndrome', 'The use of thioridazine is contraindicated in patients with congenital or acquired QT interval prolongation syndromes or a history of cardiac arrhythmias.  Thioridazine can prolong the QT interval of the electrocardiogram in a dose-related manner.  The risk of torsade de pointes is progressively increased as the degree of prolongation becomes greater.  In a crossover study of nine patients, a single 50 mg dose of thioridazine increased the QTc interval by a mean maximum of 23 msec compared to placebo.  During postmarketing experience, torsade de pointes and sudden death have been reported, although a causal relationship has not been determined.  The manufacturer states that thioridazine should not be administered in patients with a baseline QTc interval greater than 450 msec, and that it should be discontinued in patients with QTc measurements exceeding 500 msec during therapy.  Electrolyte disturbances such as hypokalemia and hypomagnesemia may augment the prolongation effect of thioridazine on the QT interval and should be corrected prior to institution of therapy.  Patients who experience frequent, severe, or prolonged diarrhea may be subject to electrolyte losses and should be followed closely and managed accordingly during therapy with thioridazine.', '3', 'Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001):  1774-82', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27805, 11385, 'Thioridazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27806, 28140, 'Thioridazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27807, 28141, 'Thioridazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27808, 11385, 'Thioridazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27809, 28140, 'Thioridazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27810, 28141, 'Thioridazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27811, 11385, 'Thioridazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27812, 28140, 'Thioridazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27813, 28141, 'Thioridazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27814, 11385, 'Thioridazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27815, 28140, 'Thioridazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27816, 28141, 'Thioridazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27817, 11385, 'Thioridazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27818, 28140, 'Thioridazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27819, 28141, 'Thioridazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27820, 11385, 'Thioridazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27821, 28140, 'Thioridazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27822, 28141, 'Thioridazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27823, 11385, 'Thioridazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27824, 28140, 'Thioridazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27825, 28141, 'Thioridazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27826, 11385, 'Thioridazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27827, 28140, 'Thioridazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27828, 28141, 'Thioridazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27829, 11385, 'Thioridazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27830, 28140, 'Thioridazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27831, 28141, 'Thioridazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27832, 11385, 'Thioridazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27833, 28140, 'Thioridazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27834, 28141, 'Thioridazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27835, 11385, 'Thioridazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27836, 28140, 'Thioridazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27837, 28141, 'Thioridazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27838, 0, 'Thiethylperazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27839, 0, 'Thiethylperazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27840, 0, 'Thiethylperazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27841, 0, 'Thiethylperazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27842, 0, 'Thiethylperazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27843, 0, 'Thiethylperazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27844, 0, 'Thiethylperazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27845, 0, 'Thiethylperazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27846, 0, 'Thiethylperazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27847, 0, 'Thiethylperazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27848, 0, 'Thiethylperazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27849, 0, 'Thiethylperazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27850, 0, 'Thiethylperazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27851, 0, 'Thiethylperazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27852, 0, 'Thiethylperazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27853, 0, 'Thiotepa', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27854, 0, 'Thiotepa', 'Liver Diseases', 'Thiotepa is rapidly metabolized by the liver to a biologically active form.  The pharmacokinetic disposition of thiotepa has not be evaluated in patients with hepatic dysfunction.  The use of thiotepa may be contraindicated in patients with existing hepatic damage.  If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage.  Clinical monitoring of hepatic function is recommended.', '3', '"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27855, 0, 'Thiotepa', 'Bone Marrow Failure Disorders', 'Thiotepa induces dose-related myelosuppression.  Therapy with thiotepa should be withheld if a white blood cell count falls below 3000/mm3 or a platelet count falls below 150,000/mm3.  If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Soloway MS, Ford KS "Thiotepa-induced myelosuppression: review of 670 bladder instillations." J Urol 130 (1983):  889-91|Watkins WE, Kozak JA, Flanagan MJ "Severe pancytopenia associated with the use of intravesical thio- TEPA." J Urol 98 (1967):  470-1|Hollister D Jr, Coleman M "Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma." JAMA 244 (1980):  2065-7|Agnelli G, de Cunto M, Gresele P, del Favero A "Early onset life-threatening myelosuppression after low dose of intravesical thiotepa." Postgrad Med J 58 (1982):  380-1', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27856, 0, 'Thiotepa', 'Kidney Diseases', 'Approximately 25% of thiotepa is eliminated by the kidney and <2% is eliminated unchanged in the urine.  The pharmacokinetic disposition of thiotepa has not be evaluated in patients with renal dysfunction.  The use of thiotepa may be contraindicated in patients with existing renal dysfunction.  If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage.  Clinical monitoring of renal function is recommended.', '3', 'Schellhammer PF "Renal failure associated with the use of thio-tepa." J Urol 110 (1973):  498-501|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27857, 0, 'Thyrotropin alfa', 'Heart Diseases', 'Thyrotropin alfa is known to cause a transient (over 7 to 14 days) but significant rise in serum thyroid hormone concentration when given to patients who have substantial thyroid tissue still in situ or functional thyroid cancer metastases, There have been reports of death in non-thyroidectomized patients and in patients with distant metastatic thyroid cancer in which events leading to death occurred within 24 hours after administration of the drug.  Patients with residual thyroid tissue at risk for thyrotropin alfa-induced hyperthyroidism include the elderly and those with a known history of heart disease.  Hospitalization for administration of therapy and post-administration observation in patients at risk should be considered.', '2', '"Product Information. Thyrogen (thyrotropin alfa)." Genzyme Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27858, 0, 'Thyrotropin alfa', 'Diseases requiring dialysis', 'The elimination of thyrotropin alfa is significantly slower in dialysis-dependent end stage renal disease (ESRD) patients, resulting in prolonged elevation of TSH levels.', '2', '"Product Information. Thyrogen (thyrotropin alfa)." Genzyme Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27859, 0, 'Thiothixene', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27860, 0, 'Thiothixene', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27861, 0, 'Thiothixene', 'Cardiovascular Diseases', 'Neuroleptic agents may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include hypertension, edema, arrhythmias, thrombophlebitis, myocarditis, angina, myocardial infarction, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with neuroleptic agents should be administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since neuroleptic agents can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Huyse F, van Schijndel RS "Haloperidol and cardiac arrest." Lancet 2 (1988):  568-9|McCance-Katz EF "New onset Raynaud''s phenomenon in a schizophrenic patient ." J Clin Psychiatry 52 (1991):  89-90|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Lieberman JA, Safferman AZ "Clinical profile of clozapine: adverse reactions and agranulocytosis." Psychiatr Q 63 (1992):  51-70|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Wilt JL, Minnema AM, Johnson RF, Rosenblum AM "Torsade de pointes associated with the use of intravenous haloperidol." Ann Intern Med 119 (1993):  391-4|Metzger E, Friedman R "Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill." J Clin Psychopharmacol 13 (1993):  128-32|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Kerwin R "Adverse reaction reporting and new antipsychotics." Lancet 342 (1993):  1440|Gupta S "Paradoxical hypertension associated with clozapine." Am J Psychiatry 151 (1994):  148|Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG "Clozapine and metabolites - concentrations in serum and clinical findings during treatment of chronically psychotic patients." J Clin Psychopharmacol 14 (1994):  119-25|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Testani M "Clozapine-induced orthostatic hypotension treated with fludrocortisone." J Clin Psychiatry 55 (1994):  497-8|Aronowitz JS, Umbricht DSG, Safferman AZ "Clozapine and new-onset ECG abnormalities." Psychosomatics 36 (1995):  82-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Baldassano CF, Ghaemi SN "Generalized edema with risperidone: divalproex sodium treatment." J Clin Psychiatry 57 (1996):  422|Ravin DS, Levenson JW "Fatal cardiac event following initiation of risperidone therapy." Ann Pharmacother 31 (1997):  867-70|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|O''Brien JM, Rockwood RP, Suh KI "Haloperidol-induced torsade de pointes." Ann Pharmacother 33 (1999):  1046-9|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezawa Y "The association between intravenous haloperidol and prolonged QT interval." J Clin Psychopharmacol 21 (2001):  257-61|La Grenade L, Graham D, Trontell A "Myocarditis and cardiomyopathy associated with clozapine use in the United States." N Engl J Med 345 (2001):  224-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27862, 0, 'Thiothixene', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Vetter PH, Proppe DG "Clozapine-induced coma." J Nerv Ment Dis 180 (1992):  58-9|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27863, 0, 'Thiothixene', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989):  962-5|Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989):  326-8|Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990):  789|Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992):  844|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  99-101|DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991):  105-7|Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991):  102-4|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993):  1561|Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983):  37-8|Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991):  572-3|Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant  syndrome" Can J Psychiatry 34 (1989):  323-5|Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994):  1228-9|Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995):  70-3|Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994):  1705|Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1233-4|Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995):  1234|Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995):  534-5|Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996):  446|Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996):  300|Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996):  775-8|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997):  617-21|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998):  485-6|Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999):  101-2|Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998):  884-6|Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999):  1115-6|Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999):  477-8|Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000):  667|SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000):  704-5|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27864, 0, 'Thiothixene', 'Hematologic Diseases', 'The use of phenothiazines has been associated with hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia has occurred frequently with large doses over prolonged periods but has generally been reversible despite continued treatment.  Since thiothixene is structurally related to the piperazine phenothiazines, the manufacturers recommend that it not be used in patients with preexisting blood dyscrasias.  Leukopenia and leukocytosis, which are usually transient, have been reported with the use of thiothixene.', '3', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Balon R, Berchou R, Zethelius M "Thrombocytopenia associated with chlorpromazine, haloperidol and thiothixene: a case report." Can J Psychiatry 32 (1987):  149-50|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27865, 0, 'Thiothixene', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27866, 0, 'Thiothixene', 'Anticholinergic Syndrome', 'Most neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low- potency agents such as chlorpromazine and thioridazine tend to exhibit the greatest degree of anticholinergic effects in the class, while haloperidol as well as the newer, atypical agents like quetiapine, risperidone and ziprasidone have generally been associated with very low frequencies of anticholinergic adverse effects.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'Grohmann R, Ruther E, Sassim N, Schmidt LG "Adverse effects of clozapine." Psychopharmacology (Berl) 99 (1989):  s101-4|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Tueth M "Side effects of clozipine (Clozaril) requiring emergency treatment." Am J Emerg Med 11 (1993):  312-3|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR "The side-effects of clozapine: a four year follow-up study." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994):  537-44|Cohen MAA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine." Am J Psychiatry 151 (1994):  619-20|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Frankenburg FR, Kando JC, Centorrino F, Gilbert JM "Bladder dysfunction associated with clozapine therapy." J Clin Psychiatry 57 (1996):  39-40|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27867, 0, 'Thiothixene', 'Dehydration', 'Neuroleptic agents may cause hypotension (including orthostatic hypotension) and associated reflex tachycardia, syncope or dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Tolerance to the hypotensive effects often develops after a few doses to a few months.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Therapy with neuroleptic agents should be administered cautiously in patients with conditions that would predispose them to hypotension, such as hypovolemia or dehydration (e.g., due to severe diarrhea or vomiting).  In addition, neuroleptic agents can interfere with the body''s ability to regulate core body temperature, occasionally producing hyperthermia during strenuous exercise, exposure to hot weather, and concomitant treatment with anticholinergic medications.  Patients who are dehydrated may be particularly susceptible.', '2', '"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27868, 0, 'Thiothixene', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27869, 0, 'Thiothixene', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27870, 0, 'Thiothixene', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27871, 0, 'Thiothixene', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27872, 0, 'Thiothixene', 'Breast Neoplasms', 'The chronic use of thiothixene is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Chronic administration of antipsychotic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with thiothixene should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', '"Product Information. Navane (thiothixene)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27873, 0, 'Thiothixene', 'Dystonia', 'Thiothixene may cause dose-related dystonic reactions, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.  These reactions are characterized by spastic contraction of discrete muscle groups that may include spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.  Therapy with thiothixene should be administered cautiously in patients, particularly males and children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.', '2', '"Product Information. Navane (thiothixene)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27874, 0, 'Thiothixene', 'Liver Failure', 'The use of thiothixene has been associated with transient elevations of serum transaminase and alkaline phosphatase.  No clinically confirmed cases of jaundice attributable to thiothixene have been reported.  Care should be exercised when using this agent in patients with liver impairment and it is recommended to monitor liver enzymes before the start of therapy and periodically thereafter as clinically appropriate.', '2', '"Product Information. Navane (thiothixene)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27875, 0, 'Thiothixene', 'Lung Diseases', 'Thiothixene may suppress the cough reflex.  Therapy with thiothixene should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', '"Product Information. Navane (thiothixene)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27876, 0, 'Tiagabine', 'Liver Diseases', 'Tiagabine is extensively metabolized by the liver.  In patients with moderately impaired hepatic function (Child-Pugh Class B), the clearance of unbound tiagabine was reduced by about 60%.  Therapy with tiagabine should be administered cautiously in patients with liver disease.  Reduced dosages and/or longer dosing intervals may be necessary in these patients.', '3', 'Mengel H "Tiagabine." Epilepsia 35 Suppl 5 (1994):  s81-4|"Product Information. Gabitril (tiagabine)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27877, 0, 'Tiagabine', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27878, 10813, 'Tiotropium', 'Angioedema', 'Angioedema has been reported during therapy with inhaled anticholinergic agents.  Therapy with these agents should be administered cautiously in patients at risk of developing angioedema and if such reaction occurs during treatment, therapy should be stopped at once and alternative treatments should be considered.  In addition, therapy with Spiriva HandiHaler should be used with caution in patients with severe hypersensitivity to milk proteins as the product contains the inactive ingredient, lactose monohydrate.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27879, 16356, 'Tiotropium', 'Angioedema', 'Angioedema has been reported during therapy with inhaled anticholinergic agents.  Therapy with these agents should be administered cautiously in patients at risk of developing angioedema and if such reaction occurs during treatment, therapy should be stopped at once and alternative treatments should be considered.  In addition, therapy with Spiriva HandiHaler should be used with caution in patients with severe hypersensitivity to milk proteins as the product contains the inactive ingredient, lactose monohydrate.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27880, 20831, 'Tiotropium', 'Angioedema', 'Angioedema has been reported during therapy with inhaled anticholinergic agents.  Therapy with these agents should be administered cautiously in patients at risk of developing angioedema and if such reaction occurs during treatment, therapy should be stopped at once and alternative treatments should be considered.  In addition, therapy with Spiriva HandiHaler should be used with caution in patients with severe hypersensitivity to milk proteins as the product contains the inactive ingredient, lactose monohydrate.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27881, 27407, 'Tiotropium', 'Angioedema', 'Angioedema has been reported during therapy with inhaled anticholinergic agents.  Therapy with these agents should be administered cautiously in patients at risk of developing angioedema and if such reaction occurs during treatment, therapy should be stopped at once and alternative treatments should be considered.  In addition, therapy with Spiriva HandiHaler should be used with caution in patients with severe hypersensitivity to milk proteins as the product contains the inactive ingredient, lactose monohydrate.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27882, 10813, 'Tiotropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27883, 16356, 'Tiotropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27884, 20831, 'Tiotropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27885, 27407, 'Tiotropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'Gross NJ "Ipratropium bromide." N Engl J Med 319 (1988):  486-94|Milford CA, Mugliston TA, Lund VJ, Mackay IS "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol 104 (1990):  123-5|Lozewicz S "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J 65 (1989):  260-1|Pras E, Stienlauf S, Pinkhas J, Sidi Y "Urinary retention associated with ipratropium bromide." DICP 25 (1991):  939-40|Massey KL, Gotz VP "Ipratropium bromide." Drug Intell Clin Pharm 19 (1985):  5-12|Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs 20 (1980):  237-66|"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):|"Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals  (2012):|"Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27886, 10813, 'Tiotropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27887, 16356, 'Tiotropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27888, 20831, 'Tiotropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27889, 27407, 'Tiotropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', '"Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim  (2002):|"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27890, 10813, 'Tiotropium', 'Hepatic Insufficiency', 'The effects of hepatic impairment on the pharmacokinetics of tiotropium have not been studied.  Caution is recommended when prescribing this agent to patients with impaired liver function.', '2', '"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27891, 16356, 'Tiotropium', 'Hepatic Insufficiency', 'The effects of hepatic impairment on the pharmacokinetics of tiotropium have not been studied.  Caution is recommended when prescribing this agent to patients with impaired liver function.', '2', '"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27892, 20831, 'Tiotropium', 'Hepatic Insufficiency', 'The effects of hepatic impairment on the pharmacokinetics of tiotropium have not been studied.  Caution is recommended when prescribing this agent to patients with impaired liver function.', '2', '"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27893, 27407, 'Tiotropium', 'Hepatic Insufficiency', 'The effects of hepatic impairment on the pharmacokinetics of tiotropium have not been studied.  Caution is recommended when prescribing this agent to patients with impaired liver function.', '2', '"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27894, 10813, 'Tiotropium', 'Kidney Diseases', 'Tiotropium is primarily eliminated unchanged by the kidney.  Renal impairment has been associated with increased plasma drug concentrations and reduced drug clearance after both intravenous infusion and dry powder inhalation.  Mild renal impairment (CrCl 50 to 80 mL/min), which is often seen in elderly patients, increased tiotropium systemic exposure (AUC) by 39% following intravenous infusion.  In COPD patients with moderate to severe renal impairment (CrCl < or equals to 50 mL/min), tiotropium AUC increased 82% following intravenous administration, which was confirmed by plasma concentrations after dry powder inhalation.  Although generally well tolerated, therapy with ipratropium should be administered cautiously in patients with moderate to severe renal impairment.  Monitoring for renal function is recommended.  Patients should be advised of and monitored for potentially increased systemic adverse effects such urinary retention.', '2', '"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27895, 16356, 'Tiotropium', 'Kidney Diseases', 'Tiotropium is primarily eliminated unchanged by the kidney.  Renal impairment has been associated with increased plasma drug concentrations and reduced drug clearance after both intravenous infusion and dry powder inhalation.  Mild renal impairment (CrCl 50 to 80 mL/min), which is often seen in elderly patients, increased tiotropium systemic exposure (AUC) by 39% following intravenous infusion.  In COPD patients with moderate to severe renal impairment (CrCl < or equals to 50 mL/min), tiotropium AUC increased 82% following intravenous administration, which was confirmed by plasma concentrations after dry powder inhalation.  Although generally well tolerated, therapy with ipratropium should be administered cautiously in patients with moderate to severe renal impairment.  Monitoring for renal function is recommended.  Patients should be advised of and monitored for potentially increased systemic adverse effects such urinary retention.', '2', '"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27896, 20831, 'Tiotropium', 'Kidney Diseases', 'Tiotropium is primarily eliminated unchanged by the kidney.  Renal impairment has been associated with increased plasma drug concentrations and reduced drug clearance after both intravenous infusion and dry powder inhalation.  Mild renal impairment (CrCl 50 to 80 mL/min), which is often seen in elderly patients, increased tiotropium systemic exposure (AUC) by 39% following intravenous infusion.  In COPD patients with moderate to severe renal impairment (CrCl < or equals to 50 mL/min), tiotropium AUC increased 82% following intravenous administration, which was confirmed by plasma concentrations after dry powder inhalation.  Although generally well tolerated, therapy with ipratropium should be administered cautiously in patients with moderate to severe renal impairment.  Monitoring for renal function is recommended.  Patients should be advised of and monitored for potentially increased systemic adverse effects such urinary retention.', '2', '"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27897, 27407, 'Tiotropium', 'Kidney Diseases', 'Tiotropium is primarily eliminated unchanged by the kidney.  Renal impairment has been associated with increased plasma drug concentrations and reduced drug clearance after both intravenous infusion and dry powder inhalation.  Mild renal impairment (CrCl 50 to 80 mL/min), which is often seen in elderly patients, increased tiotropium systemic exposure (AUC) by 39% following intravenous infusion.  In COPD patients with moderate to severe renal impairment (CrCl < or equals to 50 mL/min), tiotropium AUC increased 82% following intravenous administration, which was confirmed by plasma concentrations after dry powder inhalation.  Although generally well tolerated, therapy with ipratropium should be administered cautiously in patients with moderate to severe renal impairment.  Monitoring for renal function is recommended.  Patients should be advised of and monitored for potentially increased systemic adverse effects such urinary retention.', '2', '"Product Information. Spiriva (tiotropium)." Boehringer Ingelheim  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27898, 11770, 'Tigecycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27899, 15955, 'Tigecycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27900, 22621, 'Tigecycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27901, 27453, 'Tigecycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27902, 27978, 'Tigecycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27903, 11770, 'Tigecycline', 'Liver Diseases', 'Tigecycline is primarily metabolized by the liver and excreted in the bile as unchanged drug and metabolites.  In a single-dose study of subjects with varying degrees of hepatic impairment, systemic clearance of tigecycline was reduced by 25% and half-life prolonged by 23% in patients classified as having moderate hepatic impairment (Child Pugh B) compared to age- and weight-matched healthy control subjects.  In patients with severe hepatic impairment (Child Pugh C), systemic clearance of tigecycline was reduced by 55% and half-life prolonged by 43% compared to controls.  No significant pharmacokinetic changes were reported in patients with mild hepatic impairment (Child Pugh A).  Therapy with tigecycline should be administered cautiously in patients with severe liver disease.  The initial dose should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours.  No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.', '2', '"Product Information. Tygacil (tigecycline)." Wyeth-Ayerst Laboratories  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27904, 15955, 'Tigecycline', 'Liver Diseases', 'Tigecycline is primarily metabolized by the liver and excreted in the bile as unchanged drug and metabolites.  In a single-dose study of subjects with varying degrees of hepatic impairment, systemic clearance of tigecycline was reduced by 25% and half-life prolonged by 23% in patients classified as having moderate hepatic impairment (Child Pugh B) compared to age- and weight-matched healthy control subjects.  In patients with severe hepatic impairment (Child Pugh C), systemic clearance of tigecycline was reduced by 55% and half-life prolonged by 43% compared to controls.  No significant pharmacokinetic changes were reported in patients with mild hepatic impairment (Child Pugh A).  Therapy with tigecycline should be administered cautiously in patients with severe liver disease.  The initial dose should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours.  No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.', '2', '"Product Information. Tygacil (tigecycline)." Wyeth-Ayerst Laboratories  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27905, 22621, 'Tigecycline', 'Liver Diseases', 'Tigecycline is primarily metabolized by the liver and excreted in the bile as unchanged drug and metabolites.  In a single-dose study of subjects with varying degrees of hepatic impairment, systemic clearance of tigecycline was reduced by 25% and half-life prolonged by 23% in patients classified as having moderate hepatic impairment (Child Pugh B) compared to age- and weight-matched healthy control subjects.  In patients with severe hepatic impairment (Child Pugh C), systemic clearance of tigecycline was reduced by 55% and half-life prolonged by 43% compared to controls.  No significant pharmacokinetic changes were reported in patients with mild hepatic impairment (Child Pugh A).  Therapy with tigecycline should be administered cautiously in patients with severe liver disease.  The initial dose should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours.  No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.', '2', '"Product Information. Tygacil (tigecycline)." Wyeth-Ayerst Laboratories  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27906, 27453, 'Tigecycline', 'Liver Diseases', 'Tigecycline is primarily metabolized by the liver and excreted in the bile as unchanged drug and metabolites.  In a single-dose study of subjects with varying degrees of hepatic impairment, systemic clearance of tigecycline was reduced by 25% and half-life prolonged by 23% in patients classified as having moderate hepatic impairment (Child Pugh B) compared to age- and weight-matched healthy control subjects.  In patients with severe hepatic impairment (Child Pugh C), systemic clearance of tigecycline was reduced by 55% and half-life prolonged by 43% compared to controls.  No significant pharmacokinetic changes were reported in patients with mild hepatic impairment (Child Pugh A).  Therapy with tigecycline should be administered cautiously in patients with severe liver disease.  The initial dose should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours.  No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.', '2', '"Product Information. Tygacil (tigecycline)." Wyeth-Ayerst Laboratories  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27907, 27978, 'Tigecycline', 'Liver Diseases', 'Tigecycline is primarily metabolized by the liver and excreted in the bile as unchanged drug and metabolites.  In a single-dose study of subjects with varying degrees of hepatic impairment, systemic clearance of tigecycline was reduced by 25% and half-life prolonged by 23% in patients classified as having moderate hepatic impairment (Child Pugh B) compared to age- and weight-matched healthy control subjects.  In patients with severe hepatic impairment (Child Pugh C), systemic clearance of tigecycline was reduced by 55% and half-life prolonged by 43% compared to controls.  No significant pharmacokinetic changes were reported in patients with mild hepatic impairment (Child Pugh A).  Therapy with tigecycline should be administered cautiously in patients with severe liver disease.  The initial dose should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours.  No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.', '2', '"Product Information. Tygacil (tigecycline)." Wyeth-Ayerst Laboratories  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27908, 8509, 'Ticagrelor', 'Hemorrhage', 'Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27909, 12946, 'Ticagrelor', 'Hemorrhage', 'Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27910, 21857, 'Ticagrelor', 'Hemorrhage', 'Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27911, 28151, 'Ticagrelor', 'Hemorrhage', 'Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27912, 28155, 'Ticagrelor', 'Hemorrhage', 'Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27913, 29648, 'Ticagrelor', 'Hemorrhage', 'Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27914, 31488, 'Ticagrelor', 'Hemorrhage', 'Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27915, 8509, 'Ticagrelor', 'Liver Diseases', 'Ticagrelor is metabolized by the liver.  The use of ticagrelor should be avoided in patients with severe hepatic impairment.  Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor.  No dosage adjustment is needed in patients with mild hepatic impairment.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27916, 12946, 'Ticagrelor', 'Liver Diseases', 'Ticagrelor is metabolized by the liver.  The use of ticagrelor should be avoided in patients with severe hepatic impairment.  Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor.  No dosage adjustment is needed in patients with mild hepatic impairment.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27917, 21857, 'Ticagrelor', 'Liver Diseases', 'Ticagrelor is metabolized by the liver.  The use of ticagrelor should be avoided in patients with severe hepatic impairment.  Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor.  No dosage adjustment is needed in patients with mild hepatic impairment.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27918, 28151, 'Ticagrelor', 'Liver Diseases', 'Ticagrelor is metabolized by the liver.  The use of ticagrelor should be avoided in patients with severe hepatic impairment.  Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor.  No dosage adjustment is needed in patients with mild hepatic impairment.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27919, 28155, 'Ticagrelor', 'Liver Diseases', 'Ticagrelor is metabolized by the liver.  The use of ticagrelor should be avoided in patients with severe hepatic impairment.  Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor.  No dosage adjustment is needed in patients with mild hepatic impairment.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27920, 29648, 'Ticagrelor', 'Liver Diseases', 'Ticagrelor is metabolized by the liver.  The use of ticagrelor should be avoided in patients with severe hepatic impairment.  Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor.  No dosage adjustment is needed in patients with mild hepatic impairment.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27921, 31488, 'Ticagrelor', 'Liver Diseases', 'Ticagrelor is metabolized by the liver.  The use of ticagrelor should be avoided in patients with severe hepatic impairment.  Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor.  No dosage adjustment is needed in patients with mild hepatic impairment.', '3', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27922, 8509, 'Ticagrelor', 'Bradycardia', 'Ticagrelor can cause ventricular pauses.  Bradyarrhythmias including AV block have been reported in the postmarketing setting.  It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27923, 12946, 'Ticagrelor', 'Bradycardia', 'Ticagrelor can cause ventricular pauses.  Bradyarrhythmias including AV block have been reported in the postmarketing setting.  It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27924, 21857, 'Ticagrelor', 'Bradycardia', 'Ticagrelor can cause ventricular pauses.  Bradyarrhythmias including AV block have been reported in the postmarketing setting.  It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27925, 28151, 'Ticagrelor', 'Bradycardia', 'Ticagrelor can cause ventricular pauses.  Bradyarrhythmias including AV block have been reported in the postmarketing setting.  It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27926, 28155, 'Ticagrelor', 'Bradycardia', 'Ticagrelor can cause ventricular pauses.  Bradyarrhythmias including AV block have been reported in the postmarketing setting.  It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27927, 29648, 'Ticagrelor', 'Bradycardia', 'Ticagrelor can cause ventricular pauses.  Bradyarrhythmias including AV block have been reported in the postmarketing setting.  It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27928, 31488, 'Ticagrelor', 'Bradycardia', 'Ticagrelor can cause ventricular pauses.  Bradyarrhythmias including AV block have been reported in the postmarketing setting.  It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27929, 8509, 'Ticagrelor', 'Dyspnea', 'Dyspnea has been reported with the use of ticagrelor.  Care should be taken when prescribing this drug to patients that experienced dyspnea.  If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible.  In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27930, 12946, 'Ticagrelor', 'Dyspnea', 'Dyspnea has been reported with the use of ticagrelor.  Care should be taken when prescribing this drug to patients that experienced dyspnea.  If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible.  In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27931, 21857, 'Ticagrelor', 'Dyspnea', 'Dyspnea has been reported with the use of ticagrelor.  Care should be taken when prescribing this drug to patients that experienced dyspnea.  If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible.  In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27932, 28151, 'Ticagrelor', 'Dyspnea', 'Dyspnea has been reported with the use of ticagrelor.  Care should be taken when prescribing this drug to patients that experienced dyspnea.  If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible.  In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27933, 28155, 'Ticagrelor', 'Dyspnea', 'Dyspnea has been reported with the use of ticagrelor.  Care should be taken when prescribing this drug to patients that experienced dyspnea.  If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible.  In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27934, 29648, 'Ticagrelor', 'Dyspnea', 'Dyspnea has been reported with the use of ticagrelor.  Care should be taken when prescribing this drug to patients that experienced dyspnea.  If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible.  In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27935, 31488, 'Ticagrelor', 'Dyspnea', 'Dyspnea has been reported with the use of ticagrelor.  Care should be taken when prescribing this drug to patients that experienced dyspnea.  If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible.  In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27936, 8509, 'Ticagrelor', 'Kidney Diseases', 'No dosage adjustment is needed in patients with renal impairment.  Patients receiving dialysis have not been studied, close monitoring is recommended.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27937, 12946, 'Ticagrelor', 'Kidney Diseases', 'No dosage adjustment is needed in patients with renal impairment.  Patients receiving dialysis have not been studied, close monitoring is recommended.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27938, 21857, 'Ticagrelor', 'Kidney Diseases', 'No dosage adjustment is needed in patients with renal impairment.  Patients receiving dialysis have not been studied, close monitoring is recommended.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27939, 28151, 'Ticagrelor', 'Kidney Diseases', 'No dosage adjustment is needed in patients with renal impairment.  Patients receiving dialysis have not been studied, close monitoring is recommended.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27940, 28155, 'Ticagrelor', 'Kidney Diseases', 'No dosage adjustment is needed in patients with renal impairment.  Patients receiving dialysis have not been studied, close monitoring is recommended.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27941, 29648, 'Ticagrelor', 'Kidney Diseases', 'No dosage adjustment is needed in patients with renal impairment.  Patients receiving dialysis have not been studied, close monitoring is recommended.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27942, 31488, 'Ticagrelor', 'Kidney Diseases', 'No dosage adjustment is needed in patients with renal impairment.  Patients receiving dialysis have not been studied, close monitoring is recommended.', '2', '"Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27943, 0, 'Tilmanocept', 'Hypersensitivity', 'Tilmanocept may pose a risk of hypersensitivity reactions due to its chemical similarity to dextran and modified forms of dextran (such as iron dextran drugs).  Before administering, ask patients about prior hypersensitivity reactions to drugs, especially to dextran and modified forms of dextran.  It is recommended to have resuscitation equipment and trained personnel immediately available at the time of administration.', '2', '"Product Information. Lymphoseek (tilmanocept)." Navidea Biopharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27944, 4704, 'Tinidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27945, 25437, 'Tinidazole', 'Hematologic Diseases', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia.  The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.', '3', 'Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980):  202|White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980):  647|"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27946, 4704, 'Tinidazole', 'Neurotoxicity Syndromes', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with nitroimidazoles should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Nitroimidazole therapy should be discontinued promptly if neurologic disturbances occur.', '3', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|"Product Information. Flagyl (metronidazole)." Searle  (2002):|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Lawford R, Sorrell TC "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report." Clin Infect Dis 19 (1994):  346-8|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1|Beloosesky Y, Grosman B, Marmelstein V, Grinblat J "Convulsions induced by metronidazole treatment for Clostridium difficile-associated disease in chronic renal failure." Am J Med Sci 319 (2000):  338-9|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27947, 25437, 'Tinidazole', 'Neurotoxicity Syndromes', 'The use of nitroimidazoles (e.g., metronidazole, tinidazole) has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity.  Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods.  Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression.  Therapy with nitroimidazoles should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities.  Nitroimidazole therapy should be discontinued promptly if neurologic disturbances occur.', '3', 'Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980):  59-60|Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982):  384-7|Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983):  640-1|Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985):  1076|Duffy LF, Daum F, Fisher SE, et al. "Peripheral neuropathy in Crohn''s disease patients treated with metronidazole." Gastroenterology 88 (1985):  681-4|Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990):  19-21|Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn''s disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991):  219-24|"Product Information. Flagyl (metronidazole)." Searle  (2002):|Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994):  536|Lawford R, Sorrell TC "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report." Clin Infect Dis 19 (1994):  346-8|Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995):  588-9|Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997):  1170-1|Beloosesky Y, Grosman B, Marmelstein V, Grinblat J "Convulsions induced by metronidazole treatment for Clostridium difficile-associated disease in chronic renal failure." Am J Med Sci 319 (2000):  338-9|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27948, 4704, 'Tinidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):|"Product Information. Solosec (secnidazole)." Symbiomix Therapeutics  (2017):|"Product Information. Fexinidazole (fexinidazole)." sanofi-aventis  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27949, 25437, 'Tinidazole', 'Alcoholism', 'Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated.  Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension.  Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose.  Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake.  An alternative therapy may be appropriate.', '2', '"Product Information. Flagyl (metronidazole)." Searle  (2002):|"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):|"Product Information. Solosec (secnidazole)." Symbiomix Therapeutics  (2017):|"Product Information. Fexinidazole (fexinidazole)." sanofi-aventis  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27950, 4704, 'Tinidazole', 'Diseases requiring hemodialysis', 'The clearance of tinidazole is significantly increased during hemodialysis; the half-life is reduced from 12 hours to 4.9 hours.  During a 6-hour hemodialysis session, approximately 43% of the amount present in the body is eliminated.  If this drug is administered on the same day as and prior to hemodialysis, an additional dose of tinidazole equivalent to one-half the recommended dose should be administered after the end of the hemodialysis session.', '2', '"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27951, 25437, 'Tinidazole', 'Diseases requiring hemodialysis', 'The clearance of tinidazole is significantly increased during hemodialysis; the half-life is reduced from 12 hours to 4.9 hours.  During a 6-hour hemodialysis session, approximately 43% of the amount present in the body is eliminated.  If this drug is administered on the same day as and prior to hemodialysis, an additional dose of tinidazole equivalent to one-half the recommended dose should be administered after the end of the hemodialysis session.', '2', '"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27952, 4704, 'Tinidazole', 'Liver Diseases', 'There are no data on the pharmacokinetics of tinidazole in patients with liver dysfunction.  Reduced metabolic elimination of metronidazole (a chemically-related nitroimidazole) has been reported in patients with liver dysfunction.  Usual recommended doses of tinidazole should be administered cautiously in patients with liver dysfunction.', '2', '"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27953, 25437, 'Tinidazole', 'Liver Diseases', 'There are no data on the pharmacokinetics of tinidazole in patients with liver dysfunction.  Reduced metabolic elimination of metronidazole (a chemically-related nitroimidazole) has been reported in patients with liver dysfunction.  Usual recommended doses of tinidazole should be administered cautiously in patients with liver dysfunction.', '2', '"Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27954, 9104, 'Timolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27955, 11431, 'Timolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27956, 11433, 'Timolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27957, 11435, 'Timolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27958, 16964, 'Timolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27959, 27915, 'Timolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27960, 28196, 'Timolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27961, 9104, 'Timolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27962, 11431, 'Timolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27963, 11433, 'Timolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27964, 11435, 'Timolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27965, 16964, 'Timolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27966, 27915, 'Timolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27967, 28196, 'Timolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27968, 9104, 'Timolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27969, 11431, 'Timolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27970, 11433, 'Timolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27971, 11435, 'Timolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27972, 16964, 'Timolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27973, 27915, 'Timolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27974, 28196, 'Timolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27975, 9104, 'Timolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27976, 11431, 'Timolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27977, 11433, 'Timolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27978, 11435, 'Timolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27979, 16964, 'Timolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27980, 27915, 'Timolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27981, 28196, 'Timolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27982, 9104, 'Timolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27983, 11431, 'Timolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27984, 11433, 'Timolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27985, 11435, 'Timolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27986, 16964, 'Timolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27987, 27915, 'Timolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27988, 28196, 'Timolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27989, 9104, 'Timolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27990, 11431, 'Timolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27991, 11433, 'Timolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27992, 11435, 'Timolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27993, 16964, 'Timolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27994, 27915, 'Timolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27995, 28196, 'Timolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27996, 9104, 'Timolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27997, 11431, 'Timolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27998, 11433, 'Timolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27999, 11435, 'Timolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28000, 16964, 'Timolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);